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Abstract

DISSOCIABLE ANTIDEPRESSANT-LIKE AND ABUSE-RELATED EFFECTS OF THE
NONCOMPETITIVE NMDA RECEPTOR ANTAGONISTS KETAMINE AND MK-801 IN
RATS
By Todd M. Hillhouse, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2014
Major Director: Joseph H. Porter, Ph.D
Professor, Department of Psychology

The noncompetitive NMDA receptor antagonist ketamine produces rapid and sustained
antidepressant effects in patients suffering from major depressive disorder. However, abuse
liability is a concern. To further evaluate the relationship between antidepressant-like and abuserelated effects of NMDA receptor antagonists, this study evaluated the effects of ketamine, MK801, and phencyclidine in male Sprague-Dawley rats responding under two procedures that have
been used to assess antidepressant-like effects [differential-reinforcement-of-low-rate (DRL) 72 s
schedule of food reinforcement] and abuse-related drug effects [intracranial self-stimulation
(ICSS)]. Under DRL 72 s, ketamine produced an antidepressant-like effect by increasing
reinforcers, decreasing responses, and producing a rightward shift in the peak location of the
interresponse time (IRT) distributions. Phencyclidine produced a modest antidepressant-like
effect by increasing reinforcers and decreasing responses, but did not shift the IRT distributions.
In contrast, MK-801 produced a psychostimulant-like effect by decreasing reinforcers, increasing

responses, and producing a leftward shift in the peak location of the IRT distributions. The
antidepressant-like effects of ketamine on the DRL 72 s procedure do not appear to be mediated
by inhibiting the reuptake of serotonin via serotonin transporters or antagonism of 5-HT2
receptors. Additionally, the dissociable effects of ketamine and MK-801 in the DRL 72 s
procedure may be mediated by 5-HT2 receptors. Following acute administration, ketamine
produced only dose- and time-dependent depression of ICSS and failed to produce an abuserelated facilitation of ICSS at any dose or pretreatment time. Repeated dosing with ketamine
produced dose-dependent tolerance to the rate-decreasing effects of ketamine but failed to unmask
expression of ICSS facilitation. Termination of ketamine treatment failed to produce withdrawalassociated decreases in ICSS. In contrast, MK-801 and phencyclidine effects produced dose- and
time-dependent facilitation of ICSS by MK-801. Taken together, our findings provide further
evidence that expression of these antidepressant-like and abuse-related effects of ketamine,
phencyclidine, and MK-801 may be related to NMDA receptor affinity.

Dissociable antidepressant-like and abuse-related effects of the noncompetitive NMDA receptor
antagonists ketamine and MK-801 in rats

Major Depressive Disorder
Major depressive disorder (MDD) is the most common mood disorder in the United
States with a lifetime and a 12-month prevalence of 14.4% and 7.1%, respectively (Kessler,
Petukhova, Sampson, Zaslavsky & Wittchen, 2012). MDD is a chronic, recurring, and
debilitating mental disorder that significantly impairs occupational and/or social functioning.
Most individuals suffering from MDD have recurring depressive episodes (10.3%) rather than a
single lifetime episode (4.1%) (Kessler et al., 2012). A patient is diagnosed with chronic
depression when said patient continuously meets the DSM criteria for two or more years, and
have fewer than eight weeks of remission during that time period (American Psychiatric
Association, 2013). It is important to differentiate MDD from major depressive episode (MDE),
which includes individuals with bipolar disorder. Because of the inclusion of bipolar disorder,
MDE (16.6%) typically has higher prevalence rates compared to MDD (14.4%) (Kessler et al.,
2012). MDD also has been found to have comorbidity with other DSM disorders such as anxiety
disorder, substance abuse and impulse control disorder (Kessler et al., 2003).
Table 1 shows the diagnostic criteria for MDD. According to the Diagnostic and
Statistical Manual of Mental Disorders (DSM) 5th edition (American Psychiatric Association,
2013), an individual is required to exhibit a minimum of five depressive symptoms every day for
a period of at least two weeks, which are newly presented or clearly worsened prior to the onset
of the depressive episode, in order to be diagnosed with MDD (see table 1 for details). One of
these five symptoms must include depressed mood (Criterion A1), which is often describe mood
as being depressed or loss of interest or pleasure in hobbies or activities that were considered
pleasurable (Criterion A2). In addition to one of these two symptoms, an individual must have
1

four other depressive symptoms which may include significant changes in appetite or weight
(Criterion A3), sleep (Criterion A4), psychomotor activity (Criterion A5); loss of energy or
fatigue (Criterion A6); feelings of worthlessness (Criterion A7); diminished ability to think or
concentrate (Criterion A8); or suicidal ideation (Criterion A9). All of these symptoms, with the
exception weight lose/gain and suicidal ideation, need to be present every day for the two week
period to meet the DSM-V criterion for MDD. Furthermore, depressive episodes must
significantly impair social or occupational functioning (Criterion B). Lastly, episodes must not
be attributed to substance abuse (Criterion C) or better explained by other psychological
disorders (Criterion D and E) such as schizophrenia, bipolar, etc.
Depressive episodes may appear at any age; however, MDD is most prevalent in adults
(18-64 years) with a median age of onset in the 20s. For example, adults are twice as likely to be
diagnosed with MDD compared to both adolescents (13-17 years) and older adults (65+ years)
(Kessler et al., 2003; Kessler et al., 2012). This decline of diagnosis in older adults may be
attributed to an increase in diagnosis in adults, failure to report previous episodes, memory loss
of past episodes, or sampling bias. Females are two-to-three times more likely to be diagnosed
with MDD compared to their male counterparts regardless of age group (Kessler et al., 2012).
MDD has significant economic and social consequences, which are driven by prevalence,
medical treatment, and employment rates. For example, 36.7% of individuals suffering from
MDD are either unemployed or out of labor force and only 59.8% of the MDD population in the
workforce is receiving medical treatment for MDD (Greenberg et al., 2003). In 2000, the total
economic impact of MDD was $83.1 billion for the United States. The total direct medical
treatment costs (which include inpatient, outpatient, and pharmaceutical costs) reached $26.1
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Table 1.
Diagnostic criteria for major depressive disorder

A.

Diagnostic Criteria for Major Depressive Disorder
Five (or more) of the following symptoms that have been present during the same two
week period and represent a change from previous function.
Must include at least one of the following main symptoms:
(1) Depressed mood most of the day, nearly every day, which is indicated by either
subjective reports or observations made by others.
(2) Diminished interest or pleasure in all, or almost all, activities most of the day,
nearly every day.
Must include at least four of the following symptoms:
(3) Significant weight loss when not dieting or weight gain, or decrease or increase in
appetite nearly every day.
(4) Insomnia or hypersomnia nearly every day
(5) Psychomotor agitation or retardation nearly every day (observable by others).
(6) Fatigue or loss of energy nearly every day.
(7) Feelings of worthlessness or excessive or inappropriate guilt, nearly every day.
(8) Diminished ability to think or concentrate nearly every day (subjective or
observable by others).
(9) Recurrent thoughts of death, suicidal ideation, or suicide attempts.

B.

These symptoms cause clinically significant distress or impairment in social,
occupational, or other important areas of functioning.

C.

The episode is not attributable to the physiological effects of substance or to another
medical condition.

D.

The occurrence of the major depressive episodes is not better explained by other
disorders such as schizoaffective disorder, schizophrenia, delusional disorder, etc.

There has never been a manic episode or hypomanic episode.
E.
Adapted from Diagnostic and statistical manual of mental disorders (5th ed.) (American
Psychiatric Association, 2013)

3

billion, and suicide-related costs (i.e. estimated lost lifetime earnings) exceeded $5.4 billion.
Interestingly, workplace-related costs (e.g. missed worked days, reduced productivity, and health
care expenses) were $51.5 billion (Greenberg et al., 2003). Individuals with severe MDD cost
their employers approximately double in health care expenses, are more likely to file for
disability and/or be unemployed, and missed approximately 13.7 MORE hours per month as
compared to healthy individuals (Birnbaum et al., 2010).
Monoamine Hypothesis and Monoamine Based Pharmacological Treatments
It has been almost 50 years since the monoamine hypothesis of depression was
articulated. The monoamine hypothesis proposes that patients with depression have depleted
concentrations of serotonin, norepinephrine, and dopamine (Bunney & Davis, 1965; Delgado,
2000; Hirschfeld, 2000; Schildkraut, 1965). There are two primary lines of evidence that led to
the development of this monoamine hypothesis: 1) the effects of reserpine on serotonin; and 2)
the pharmacological mechanisms of action of antidepressant drugs. Reserpine, an alkaloid
extracted from the Rauwolfia serpentina, was utilized as a treatment for hypertensive vascular
disease in the 1950s; however, reserpine was found to precipitate depression in some patients.
The depression produced by reserpine was reversed after the treatment was terminated, and
following either rest or electric shock therapy (Muller, Pryor, Gibbons, & Orgain, 1955).
Additionally, reserpine was found to produce depressive-like effects in animals (Hirschfeld,
2000). Reserpine was found to depleted brain serotonin (Shore, Pletscher, Tomich, Carlsson,
Kuntzman, & Brodie, 1957; Shore, Silver, & Brodie, 1955), which provided evidence for the role
of serotonin in depression. The second line of evidence centered on the underlying
pharmacological mechanisms of action of antidepressant drugs. For example, antidepressant
treatments primarily target the monoamine neurotransmitters (i.e. serotonin, norepinephrine, and
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dopamine) in an attempt to enhance the presence of monoamine neurotransmitters in the synaptic
space to activate postsynaptic receptors (see below for the mechanism of action for each
antidepressant drug class).
Much like the discovery of the first antipsychotic drug chlorpromazine, the first
pharmacological treatment for depression was discovered by serendipity. Chemists at HoffmannLa Roche Ltd USA developed isonicotinyl hydrazide (isoniazid) for the treatment of
tuberculosis. Isoniazid was a successful antitubercular compound as the mortality rate of
tuberculosis significantly decreased after being on the market for only one year (Lopez-Munoz,
Alamo, Juckel, & Assion, 2007; Pletscher, 1991). While developing new antitubercular
compounds, Fox and Gibas (1953) synthesized isopropyl-isonicotinyl hydrazide (iproniazid), a
monoalkyl derivative of isoniazid, which would later serve as a catalyst for pharmacological
treatment of MDD. Clinical observations reported marked “side effects” of iproniazid in patients
being treated for tuberculosis, which included euphoria, psychostimulation, increased appetite,
and improved sleep. The “side effects” produced by iproniazid were not originally identified as
therapeutic effects because these side effects were not consistent across studies (Lopez-Munoz et
al., 2007; Pletscher, 1991). Loomer, Saunders, and Kline (1958) conducted a systematic clinical
study on patients with depression, in which these patients were treated with iproniazid for several
weeks. Loomer and colleagues reported significant improvements in 70% of these patients
(Loomer et al., 1958). In 1958, iproniazid was marketed as an antitubercular compound under the
trade name Marsilid®; however, iproniazid was used off-label to treat patients suffering from
MDD.
Thus, iproniazid served as the first pharmacological treatment for depression and is
classified as a monoamine oxidase (MAO) inhibitor. MAO is an enzyme that produces oxidative
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disamination (or break down) of biogenic amines (e.g. serotonin, dopamine, epinephrine, and
norepinephrine) and sympathomimetic amines (e.g. tyramine, benzylamine, etc). There are two
isoenzymes, MAOA and MAOB, and the distribution of these isoenzymes varies throughout the
body. MAOA is primarily responsible for the enzyme activity in the peripheral tissue and for the
deaminate of serotonin, melatonin, noradrenaline, and adrenaline (Billett, 2004; Shulman,
Herrman, & Walker, 2013). In contrast, MAOB is responsible for enzyme activity in the brain
and for the breakdown of phenethylamine, and benzylamine (Campbell, Marangos, Parma,
Garrick, & Murphy, 1982; Shulman et al., 2013). Interestingly, both isoenzymes deaminate
dopamine, tyramine, and tryptamine. MAOs responsible for the breakdown of biogenic amines
are located in the presynaptic terminal. A result of inhibiting MAO is that monoamine
neurotransmitters concentrations increase in the presynaptic terminal and are readily available
for release when action potential reaches the nerve terminal. Iproniazid is a non-selective
irreversible MAO inhibitor, which led to safety concerns (e.g. hypertensive crises), and
ultimately led to the removal of iproniazid from the US market. One example of the safety
concern was termed the “cheese reaction”. The combination of foods containing high amounts of
tyramine, such as cheese or dairy products, and MAO inhibitors, which increase concentrations
of tyramine and norepinephrine in the sympathetic nervous system, would lead to increased heart
rate, hypertension and sweating. It was later determined that inhibiting the MAOA was
functionally involved in the antidepressant effects of MAO inhibitors (Lopez-Munoz et al., 2007;
Shulman et al., 2013). In an attempt to improve the safety of MAO inhibitors, drug development
focused on reversible and selective MAOA inhibitors (e.g. brofaromine and moclobemide).
As a result of the discovery and success of chlorpromazine for the treatment of
schizophrenia, the search for more potent antipsychotic drugs intensified. Many of these novel
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compounds used the classic antihistamine structure, and were molecularly modified. One
compound in particular, G22355 (imipramine), was derived from promethazine by substituting
the sulfur bridge of the phenothiazine ring with an ethylene bridge, and shared the same side
chain as chlorpromazine (Domino, 1999; Fangmann, Assion, Juckel, Gonzalez, & Lopez-Munoz,
2008). The Geigy Chemical Corp supplied imipramine, which was synthesized by Hafliger and
Schinder, to Dr. Roland Kuhn to test in psychiatric patients. Although imipramine did not exhibit
antipsychotic properties in patients with schizophrenia, Kuhn found that imipramine produced
marked improvements in patients suffering from severe depression. In an essay written by Kuhn
(1958), he states “They commence some activity of their own, again seeking contact with other
people, they begin to entertain themselves, take part in the games, become more cheerful and are
once again able to laugh… The patients express themselves as feeling much better, fatigue
disappears, the feeling of heaviness in the limbs vanish, and the sense of oppression in the chest
gives way to a feeling of relief” (p. 459). Kuhn also stated that no serious side effects were
recorded in the 500 patients treated with imipramine, which was a vast improvement over MAO
inhibitors.
Imipramine was approved in 1959 by the Food and Drug Administration (FDA) for the
treatment of MDD, which established the class of drugs called tricyclic antidepressants. Tricyclic
antidepressants are classified based on the three benzene ring molecular core, in part, because the
mechanism of action was unknown at the time of discovery. Thus, the classification of tricyclic
antidepressant differs that of other classes of antidepressant drugs, which are classified based on
their mechanism of action. Tricyclic antidepressants have a diverse pharmacological profile with
significant pharmacological action at five transporter/receptor proteins: inhibiting presynaptic
norepinephrine reuptake transporters; inhibiting presynaptic serotonin reuptake transporters;
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blocking postsynaptic adrenergic α1 and α2 receptors; blocking postsynaptic muscarinic
receptors; and blocking postsynaptic histamine H1 receptors (Cusack, Nelson, & Richelson,
1994; Owens, Morgan, Plott, & Nemeroff, 1997; Sánchez & Hyttel, 1999: Vaischnavi et al.,
2004). The inhibitions of norepinephrine and serotonin reuptake at the transport proteins are
thought to be responsible for the therapeutic effects of tricyclic antidepressants, and result in
increased concentrations of norepinephrine and serotonin in the synaptic cleft, respectively. The
selectivity for norepinephrine or serotonin transporters depends on the compounds; however,
most tricyclic antidepressants are more selective for the norepinephrine transporter over the
serotonin transporter (Owens et al., 1997; Sánchez & Hyttel, 1999; Thomas, Nelson, & Johnson,
1987). The antagonism of histaminergic, adrenergic, and muscarinic receptors contribute
primarily to the side effects (e.g. drowsiness, memory impairments, and dizziness, respectively)
of tricyclic antidepressants.
In the late 1960s evidence began to emerge suggesting a significant role of serotonin in
MDD. For example, a postmortem study revealed decreased concentrations of serotonin in
depressive suicides (Shaw, Eccleston, & Camps, 1967). As a result, the pharmaceutical company
Eli Lilly began developing ligands that would selectively inhibit the reuptake of serotonin at the
serotonin transporter and as a result would increase serotonin concentrations within the synaptic
cleft to further stimulate postsynaptic serotonin receptors. In 1974, the first report on the
selective serotonin reuptake inhibitor (SSRI) fluoxetine was published and in that publication the
authors suggested that fluoxetine would be an antidepressant drug (Wong, Bymaster, &
Engleman, 1995; Wong, Perry, & Bymaster, 2005). The following year Wong and colleagues
demonstrated that fluoxetine was a potent and selective serotonin reuptake inhibitor with
relatively weak affinity for the norepinephrine transporter (Wong, Bymaster, Horng, & Molloy,
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1975). Fluoxetine was approved by the FDA in December of 1987 and was launched to the
market in January 1988 under the trade name Prozac®. Since the introduction of fluoxetine to
the market, several other SSRIs have been approved by the FDA (e.g. sertraline, citalopram, and
paroxetine).
SSRIs are 20-1500 fold more selective for inhibiting serotonin over norepinephrine at
their respective transporter proteins and have no significant (or weak) binding affinity for other
receptors such adrenergic α1, α2, and β, histamine H1, muscarinic, or dopamine D2 receptors
(Owens et al., 1997; Thomas et al., 1987). SSRIs (e.g. fluoxetine and citalopram) do not
stimulate the release of serotonin or norepinephrine (Rothman et al., 2001) and have weak or no
pharmacological action at postsynaptic serotonin receptors (e.g. 5-HT1A, 5-HT2A, and 5-HT2c)
(Owens et al., 1997; Sánchez & Hyttel, 1999; Thomas et al., 1987). Therefore, the increase in
activity at the postsynaptic serotonin receptors produced by SSRIs is a result of increased
concentrations of serotonin in the synaptic cleft via reuptake inhibition rather than direct binding
at the postsynaptic receptor. The most common side effects associated with SSRIs are nausea,
insomnia, and sexual dysfunction (Papakostas, 2008).
Several “atypical” antidepressant drugs have been developed in the past couple of
decades; however, for the most part, the mechanisms of action for these drugs are similar to
established antidepressant drugs. For example, serotonin-norepinephrine reuptake inhibitors
(SNRI) are similar to tricyclic antidepressants in that SNRIs inhibit the reuptake of serotonin and
norepinephrine at the serotonin and norepinephrine transporters, respectively. Unlike tricyclic
antidepressants, SNRIs (e.g. duloxetine, venlafaxine, and milnacipran) do not have significant
pharmacological action at adrenergic α1, α2, and β, histamine H1, muscarinic, dopamine, or
postsynaptic serotonin receptors (Bymaster et al., 2001; Millan et al., 2001; Owens et al., 1997;

9

Sánchez & Hyttel, 1999; Vaischnavi et al., 2004). While SNRIs have greater receptor selectivity
as compared to tricyclic antidepressant drugs, the clinical efficacy and tolerability of SNRIs are
similar to SSRIs (Stahl, Grady, Moret, & Briley, 2005).
Bupropion is an “atypical” antidepressant drugs with a unique binding profile as
compared to other antidepressant drugs (e.g. tricyclic, SSRI, SNRI). For example, bupropion is
primarily a dopamine reuptake inhibitor, although the binding affinity of bupropion for
dopamine transporters is modest (Bymaster et al., 2002; Letchworth et al., 2000; Pristupa,
Wilson, Hoffman, Kish, & Niznik, 1994). Bupropion is at least two-fold more selective for
dopamine transporters as compared to norepinephrine and serotonin transporters and does not
display significant binding affinity for other receptors (Bymaster et al., 2002; Cusack et al.,
1994; Sánchez & Hyttel, 1999). A review of the clinical research shows that bupropion is at least
as tolerable and efficacious as other antidepressant drugs (Moreira, 2011).
Nonpharmacological Treatments for Major Depressive Disorder
There are several nonpharmacological treatment therapies for MDD. For example,
cognitive behavioral analysis system of psychotherapy (CBASP) and cognitive behavioral
therapy (CBT) focus on resolving current problems and understanding the connection between
behavior and consequences (McCullough, 2000). Both CBASP and CBT has been shown to
significantly decrease scores on several depressive scales, such as Hamilton Rating Score for
Depression and Beck Depression Inventory, with an efficacy similar to pharmacological
antidepressant (Keller et al., 2000; Swan et al., 2014; Zu et al., 2014). A large scale clinical study
compared the effects of pharmacological therapy (nefazodone, a potent serotonin 5-HT2A
receptor antagonist), CBASP, and the combination of nefazodone and CBASP over a 12-week
study and found that all three groups showed a significant improvement according to the
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Hamilton Rating Score for Depression-24 scale. However, the combined treatment group
(nefazodone + CBASP) showed significantly greater improvement as compared to the
nefazodone alone and CBASP alone groups. The combination treatment group achieved 42%
remission; whereas, the nefazodone alone and CBASP alone group achieved 22% and 24%
remission, respectively (Keller et al., 2000). However, the effectiveness of the CBT and
antidepressant combination treatment have been mixed with some clinical studies showing
increased efficacy (Ma, Zhang, Zhang, & Li, 2014) and other clinical studies failing to find an
improvement over antidepressant treatment alone (Goodyer et al., 2007; Zu et al., 2014).
Treatment-Resistant Depression
Although there are several treatment options (both pharmacological and
nonpharmacological) for MDD, 34-46% of MDD patients do not adequately response to
treatment (Fava & Davidson, 1996). These patients are categorized as having treatment-resistant
depression, which typically is defined as an inadequate response (i.e. fail to achieve full
remission) to one or more antidepressant treatment following adequate duration and dose (Fava
& Davidson, 1996; Fava, 2003). Treatment-resistant depression is well documented in the
literature and is accepted as a subtype of depression; however, there is not a unified definition.
For this dissertation, the definition above (i.e. full remission) will be used because the goal for
treatment should be to return the patient to the premorbid state of social and occupational
functioning. An additional serious issue for treatment of MDD is that even for the patients that
do respond to current antidepressant drugs, there is a delayed onset of 4-12 weeks before
adequate symptom remission is achieved (Schulberg, Katon, Simon, & Rush, 1998; Uher et al.,
2011).
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Although limited, some progress has been made in both preclinical and clinical research
to address the issue of treatment-resistant depression. For example, preclinical animal models,
such as chronic mild stress and social defeat model, have been developed in order to mimic
treatment-resistant depression (Samuels, 2011). In clinical research, one group has developed a
strategic plan for treatment-resistant depression called Sequenced Treatment Alternatives to
Relieve Depression (STAR*D). STAR*D provides a four step treatment plan, in which a patient
proceeds to the next treatment step if they do not achieve full remission under the current
treatment step (Fava et al., 2003). SSRIs are the first treatment step and as patients progress
through the treatment steps they will be introduced to new antidepressant drugs with different
mechanism of actions (e.g. SNRIs, bupropion, and tricyclics). Patients that achieve full remission
and tolerate treatment at a specific step are then placed on long term treatment with that drug.
Although the STAR*D provides clinicians with guidelines and a strategic plan for treating
treatment-resistant depression, the results from a large-scale long-term study showed that
patients who progress through more treatment steps had higher relapse rates as compared to
patients that achieved remission in the first treatment step (Rush et al., 2006).
Experimental approaches such as deep brain stimulation (Bewernick et al., 2010;
Bewernick, Kayser, Sturm, & Schlaepfer, 2012; Cook, Espinoza, & Leuchter, 2014; Mayberg et
al., 2005; Schlaepfer, Bewernick, Kayser, Mädler, & Coenen, 2013; Williams & Okun, 2013)
and electroconvulsive therapy (Eschweiler et al., 2007; Kellner et al., 2012; Khalid et al., 2008),
have shown promised as a treatment for treatment-resistant patients. Clinical research also has
suggested that the use of atypical antipsychotic drugs as adjunctive treatments with
antidepressant drugs may be effective for treatment-resistant depression (Chen, & Tzeng, 2013;
Li, Xing, Yu, Chen, & Wu, 2013; Šagud, Mihaljević-Peleš, Mück-Šeler, Jakovljević, & Pivac,
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2006; Tohen et al., 2010; Wright, Eiland, & Lorenz, 2013). More recently, research has focused
on finding novel, non-monoaminergic based, receptor targets for treatment-resistant depression.
In particular, the glutamatergic system has become a focal point for drug development research.
Glutamatergic Systems and Major Depressive Disorder
Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS),
and is present at over 60% of synapses. The fact that glutamate acts as a rapid excitatory
transmitter, combined with its prevalence, suggests that glutamate may be involved in abnormal
circuitries, and may facilitate or even cause disease symptoms. The glutamate system has an
integrated tripartite synapse that consists of 1) a presynaptic neuron, 2) a postsynaptic neuron,
and 3) an astrocyte. The presynaptic neuron releases glutamate in response to action potentials.
The released glutamate then binds to various pre- and postsynaptic receptors, as well as receptors
on the surrounding astrocytes. Synaptic glutamate reuptake is performed primarily by astrocytes,
specifically, the excitatory amino acid transporter 2 (EAAT2). Within the astrocyte, glutamate is
converted to glutamine (glutamate/glutamine cycle) via glutamate-ammonia ligase (glutamine
synthetase) and then resupplied to the presynaptic neuron where it is used for synthesis of
glutamate (Kew & Kemp, 2005; Machado-Vieira, Manji, & Zarate, 2009; Mathews, Henter, &
Zarate, 2012).
Like many neurotransmitters, glutamate acts on two types of receptors, ionotropic and
metabotropic. Ionotropic glutamatergic receptors include α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA), kainate, and N-methyl-D-aspartate (NMDA) receptors. These
receptors are ion channels that are permeable to cations and function by allowing sodium (Na+)
and calcium (Ca2+) ions to enter the cell, thus causing depolarization and other intracellular
changes (Kew & Kemp, 2005). Eight subtypes of metabotropic glutamate receptors (mGluR1-8)
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are divided into Group I (mGluR1 and mGluR5), Group II (mGluR2 and mGluR3), and Group
III (mGluR4, mGluR6, mGluR7, and mGluR8) based upon their homology and function. These
receptors are G-protein-coupled receptors (GPCRs) and function by either influencing
intracellular second messenger formation, and/or releasing G protein, subunits which influence
ion channel activity (Kew & Kemp, 2005; Pin & Duvoisin, 1995). Assessing all glutamate
receptors and their respective implications in major depressive disorder would be beyond the
scope of this dissertation. Therefore, this dissertation will primarily focus on NMDA receptors
(for a review on the role of mGluR in pathophysiology and treatment of MDD please see Holly,
LaCrosse, & Hillhouse, In Press).
NMDA receptors are a heteromeric complex that has seven subunits, NR1, NR2A-D, and
NR3A-B and functional NMDA receptors must be comprised of a NR1 subunit and at least one
NR2 subunit. Unlike other ligand-gated ion channels, NMDA receptors require two distinct
mechanisms in order to be activated. First, NMDA receptor channels require co-agonist binding
at the glycine binding site on the NR1 subunit and at the glutamate binding site on the NR2
subunit (Kew & Kemp, 2005; Marsden, 2011). Thus, if one of these co-agonists (glycine or
glutamate) is not bound to their respective binding site, the ion channel will not open. Second,
the NMDA receptor channels are blocked by magnesium (Mg2+) ions during the resting state.
Depolarization of the neuron is required to dispel the Mg2+ ion from NMDA receptor channels,
which is usually achieved by activation of AMPA receptors. The NMDA receptor ion channel is
non-selective and will allow both Na+ and Ca2+ to enter. The influx of Ca2+ is associated with the
induction of various signaling cascades (Kew & Kemp, 2005; Marsden, 2011).
The glutamatergic system has emerged as a potential target to improve clinical efficacy
and onset of remission for the treatment of MDD. Both clinical and postmortem research has
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provided evidence of glutamatergic dysfunction in patients diagnosed with MDD. For example,
elevated concentrations of glutamate, glutamine, glycine, and serine have been found in patients
with MDD using indirect measures such as plasma, serum, or cerebrospinal fluid (Altamura et
al., 1993; Kim, Schmid-Burgk, Claus, & Kornhuber, 1982; Küçükibrahimoğlu et al., 2009;
Levine et al., 2000; Mauri et al., 1998; Mitani et al., 2006; Sumiyoshi et al., 2004). Additionally,
MDD patients have shown a greater sensitivity to glutamate as measured by intracellular calcium
influx (Berk, Plein, & Ferreira, 2001). Furthermore, antidepressant drug treatment has been
found to reduce the serum glutamate (Maes, Verkerk, Vandoolaeghe, Lin, & Scharpé, 1998),
cerebrospinal fluid glutamine (Garakani, Martinez, Yehuda, & Gorman, 2013), and plasma
glutamate and glutamine concentrations in MDD patients (Küçükibrahimoğlu et al., 2009).
However, there is evidence that has shown decreased concentrations of glutamate and glycine in
cerebrospinal fluid (Frye et al., 2006), as well as decreased concentrations of glutamine and
glycine in blood plasma (Altamura et al., 1993; Altamura et al., 1995).
These indirect measures of glutamate in CSF, plasma, and serum are difficult to interpret,
as these disruptions may be due to medication, metabolic effects, or the inability of these
methods to distinguish between central and peripheral glutamate (see table 2). As such, proton
magnetic resonance spectroscopy (1H-MRS) has been used to more directly measure
neurotransmitter concentration, specifically glutamate/glutamine (Glx), in adults with severe
depression (see table 3). 1H-MRS studies have shown reduced Glx in the anterior cingulate
cortex (Auer et al., 2000; Pfleiderer et al., 2003), hippocampus (Block et al., 2009), left
dorsolateral prefrontal cortex (Michael et al., 2003), dorsomedial and ventromedial prefrontal
cortex (Hasler et al., 2007) of adult MDD patients. Moreover, a 19% reduction in glutamate and
glutamine has been observed in adolescent patients with severe MDD (Mirza et al., 2004).
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Following ECT treatment, the anterior cingulate cortex and left dorsolateral prefrontal cortex Glx
concentrations were significantly increased and recovered back to health control Glx
concentrations (Michael et al., 2003; Pfleiderer et al., 2003). However, one study has shown
increased glutamate concentrations in the occipital cortex (Sanacora et al., 2004). Furthermore,
Hashimoto and colleagues found elevated concentrations of glutamate in the frontal cortex of
postmortem tissue from patients with MDD (Hashimoto, Sawa, & Iyo, 2007). Additionally, the
high affinity glial glutamate transporter (EAAT2), the main source the glutamate reuptake, has
been shown to be down-regulated in postmortem brain tissue in MDD patients (Bernard et al.,
2001; Choudary et al., 2005).
In combination with significant alterations in glutamate and glutamine, concentrations of
NMDA receptor subunit expression are altered in patients with MDD (see table 4). For example,
the NR2A and NR2B subunits have been shown to be reduced in the perirhinal and prefrontal
cortices in postmortem tissue from MDD patients (Beneyto, Kristiansen, Oni-Orisan,
McCullumsmith, & Meador-Woodruff, 2007; Feyissa, Chandran, Stockmeier, & Karolewicz,
2009). Additionally, Nudmamud-Thanoi and Reynolds (2004) found decreased levels of the NR1
subunit in the superior temporal cortex. In contrast, the NR2A and NR2C subunits have been
found to be elevated in the lateral amygdala (Karolewicz et al., 2009) and locus coeruleus
(Karolewicz, Stockmeier, & Ordway, 2005), respectively.
Taken together, these results suggest a bi-directional glutamatergic dysfunction in MDD,
with disruptions both in glutamate/glutamine cycling and glutamatergic receptor expression.
Although the role of glutamatergic system has yet to be fully elucidated, a “proof of concept”
clinical study reported that the noncompetitive the NMDA antagonist ketamine produces rapid
and prolonged antidepressant effects in patients suffering from MDD (Berman et al., 2000).
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Table 2.
Glutamatergic dysfunction in major depressive disorder using indirect measures for analysis

Interest
Glutamate

Region of Analysis
Serum
Plasma

Glutamine

Change
Increased
Decreased
Increased

Cerebrospinal fluid
Platelet-rich plasmac

Decreased
Supersensitivity
to glutamate

Serum
Plasma
Cerebrospinal fluid

Increased
Decreased
Increased
Decreased
Decreased

Maes et al., 1998a
Altamura et al., 1993
Levine et al., 2000
Garakani et al., 2013b
Frye et al., 2007

Increased
Mitani et al., 2006
Decreased
Altamura et al., 1995
a
decrease after 5-week antidepressant; however, no difference prior to treatment
b
decrease after 8-week antidepressant; however, no difference prior to treatment
c
platelet intracellular calcium response to glutamate stimulation
Glycine

Plasma

Reference
Kim et al., 1982
Maes et al., 1998a
Altamura et al., 1993
Mauri et al., 1998
Mitani et al., 2006
Küçükibrahimoğlu et al., 2009
Frye et al., 2007
Berk et al., 2001
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Table 3.
Glutamatergic levels measured by proton magnetic resonance spectroscopy (1H-MRS)
Interest
Glutamate/
Glutamine
(Glx)

Region of Analysis
Occipital cortex
Anterior cingulate cortex

Change
Increased
Decreased

Reference
Sanacora et al., 2004
Auer et al., 2000
Pfleiderer et al., 2003a
Block et al., 2009b
Michael et al., 2003a
Hasler et al., 2007

Hippocampus
Decreased
Dorsolateral prefrontal cortex
Decreased
Dorsomedial and ventromedial
Decreased
prefrontal cortex
a
Glx major depressive disorder levels recovered to healthy control following ECT treatment
b
no change in Glx levels following 8-weeks of citalopram treatment
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Table 4.
Alterations in NMDA receptor subunit expression

Receptor
Region of
Subunit/site Analysis
Superior
NR1
temporal cortex
Prefrontal cortex
Perirhinal cortex
NR2A
Lateral amygdala

NR2B
NR2C

Prefrontal cortex
Perirhinal cortex
Prefrontal cortex
Locus coeruleus

Hippocampus
Glutamate
Binding site

Molecular Assay

Change

Reference

Western blot

Decreased

Western blot
In situ hybridization
Western blot

No change
Decreased
Increased

Western blot
In situ hybridization
Western blot
Western blot

Decreased
Decreased
Decreased
Increased

Autoradiography

Decreased
binding

Nudmamud-Thanoi et
al., 2004
Feyissa et al., 2009
Beneyto et al., 2007
Karolewicz et al.,
2009
Feyissa et al., 2009
Beneyto et al., 2007
Feyissa et al., 2009
Karolewicz et al.,
2005
Beneyto et al., 2007
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Ketamine: Antidepressant and Drug of Abuse
Ketamine, a dissociative anesthetic with hallucinogen properties, is a derivative of
phencyclidine and was developed in the 1960s by Dr. Calvin Lee Stevens of Wayne State
University for the pharmaceutical company Parke-Davis. In 1964, ketamine was experimentally
administered to human subjects to test the safety and general anesthetic properties of ketamine.
The subjects reported low side effects and described feelings of floating or having no feeling in
their limbs. Ketamine was approved by the FDA in 1970 for use as a short-acting anesthetic in
humans and animals, and was given to injured American soldiers during the Vietnam War
(Domino, 2010). In 1999, ketamine became a Schedule III non-narcotic substance under the
Controlled Substances Act (Drug Enforcement Administration, 2013). Ketamine, which is
distributed under the trade names Ketalar®, Ketaset®, Vetamine®, is still widely used in human
and veterinary medicine with approximately 16,000 dispensed ketamine prescriptions in 2012
(Domino, 2010; Drug Enforcement Administration, 2013).
Ketamine is a noncompetitive NMDA receptor antagonist (aka channel blocker) that
binds to the phencyclidine site inside the ion channel of the NMDA receptor, similarly to Mg2+,
and is non-selective for the NR2A-D subunits of the NMDA receptor channel (Lord et al., 2013;
Yamakura, Mori, Masaki, Shimoji, & Mishina, 1993; Yamakura & Shimoji, 1999). While many
have categorized ketamine as a high affinity NMDA receptor antagonists, in vivo
autoradiography studies suggest that ketamine has relatively low affinity for the NMDA receptor
(Ki = 659-1190 nM) (Bresink, Danysz, Parsons, & Mutschler, 1995; Roth et al., 2013).
Additionally, selectivity of ketamine for the NMDA receptor appears to be weak compared to
other receptors (see table 5). For example, ketamine has been shown to have higher receptor
affinity for in vitro human cloned dopamine D2 receptors (Ki = 55 nM) compared to NMDA
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receptors (Seeman, Ko, & Tallerico, 2005); however, a follow up study found that ketamine did
not exert functional activity (i.e. as a full agonist, partial agonist, or antagonists) at in vitro
dopamine D2 receptors (Jordan et al., 2006). Furthermore, ketamine is approximately 12 to 20fold more selective for NMDA receptors as compared to serotonin 5-HT2A and mu opioid
receptors (Kapur & Seeman, 2002; Smith et al., 1987). Ketamine also has considerable binding
affinity for sigma (Mendelsohn, Kalra, Johnson, & Kerchner, 1985), muscarinic, and opioid (κ
and δ) receptors (Hirota, Hashimoto, & Lambert, 2002), as well as dopamine, norepinephrine,
and serotonin transporters (Nishimura et al., 1998). Moreover, several behavioral procedures,
such as forced swim test, drug discrimination, novelty-suppressed feeding, tail suspension and
hypothermia, have shown the involvement of serotonin mechanisms in the behavioral effects of
ketamine (Fahim, Ismail, & Osman, 1973; Fukumoto, Iijima, & Chaki, 2014; Gigliucci et al.,
2013; Kos et al., 2006; Yoshizawa et al., 2013)
Ketamine, also known as “Special K,” became popular as a recreational drug in the mid1990s. Although the illicit used of ketamine appears to be relatively low in the United States
with less than 2% of the population using hallucinogens (Substance Abuse and Mental Health
Services Administration, 2013), which also include lysergic acid diethylamide, phencyclidine,
peyote, mescaline, psilocybin mushrooms, and “ecstasy,” the popularity of ketamine continues to
grow in other countries. For example, ketamine (23.2%) is the second most abused substance in
Hong Kong with heroin (61.7%) being the most abused substance (Shek, 2007). The use of
ketamine has been on a rise over the past decade, specifically among “dance” or “club” drug
users in Europe, which may be in part to the decline of Lysergic acid diethylamide usage
(McCambridge, Winstock, Hunt, & Mitcheson, 2007, 2007; Shek, 2007; Winstock, Mitcheson,
Gillatt, & Cottrell, 2012). At subanesthetic or emergence from anesthetic doses, ketamine
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Table 5.
Receptor binding affinities for ketamine.
N/A, not applicable; NMDA, N-methyl-D-aspartate; PCP, phencyclidine.
Receptor/region
Ketamine
Citation
Ki (µM)
NMDA (PCP site)
Cortex
1.190 ± 0.237
Bresink et al, 1995
Cerebellum
2.507 ± 1.900
Bresink et al, 1995
Striatum
3.100 ± 0.300
Seeman et al, 2005
3-D model
0.420
Tikhonva et al, 2004
a
Dopamine D2
0.055 ± 0.012
Seeman et al, 2005
Norepinephrine Transporter (NET)
66.8 ± 25.9b
Nishimura et al, 1998
c
Dopamine Transporter (DAT)
62.9 ± 2.3
Nishimura et al, 1998
Serotonin Transporter (SERT)
161.7 ± 28.3d
Nishimura et al, 1998
Serotonin
5-HT2
15.0 ± 5.0
Kapur et al, 2002
Opiate receptor
Mu (µ)
26.8 ± 2.7
Smith et al, 1987
Delta (δ)
101 ± 9.0
Smith et al, 1987
Kappa (κ)
85.2 ± 26.0
Smith et al, 1987
Sigma (σ)
66.0 ± 10.0
Smith et al, 1987
Muscarinic
M1
45.0e (SEM n/a)
Hirota et al., 2002
a
Chinese hamster ovary (CHO) cells (human cloned dopamine D2long receptors).
b
Transfected human embryonic kidney (HEK 293) cells (human NET).
c
Transfected human embryonic kidney (HEK 293) cells (rat DAT).
d
Transfected human embryonic kidney (HEK 293) cells (rat SERT).
e
Chinese hamster ovary (CHO) cells (human cloned Muscarinic M1 receptors).
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produces hallucinations (i.e. distorts perceptions of sight and sounds), mood and body image
changes, and make the user feel disconnected (or dissociated) from their body/reality. The
hallucinogenic effects of ketamine have been termed the “K-hole” by users, and the duration of
these effects are relatively short, 30 to 60 min, compared to phencyclidine (Drug Enforcement
Administration, 2013).
In 2000, the noncompetitive NMDA receptor antagonist ketamine was first used in a
“proof of concept” randomized, double-blinded study to assess the effects of ketamine on MDD
patients. A single, subanesthetic dose (0.5 mg/kg) of ketamine was intravenously infused over 40
minutes, and the antidepressant effects of ketamine were assessed using the Hamilton Depression
Rating Scale and Beck Depression Inventor. In comparison, an anesthetic dose for ketamine in
humans ranges from 1.0 mg/kg to 4.5 mg/kg intravenous and from 6.5 mg/kg to 13.0 mg/kg
intramuscular. In this study, ketamine produced rapid, within 4 hours, and prolonged
antidepressant effects that lasted up to 72 hours as compared to placebo control (Berman et al.,
2000). This rapid antidepressant effect of ketamine is far superior to the 4-12 week delay with
current antidepressant drugs (Schulberg et al., 1998; Uher et al., 2011). The hallucinogenic
effects of ketamine subsided prior to the onset of the antidepressant effects as measured by the
Visual Analog Scales for intoxication “high” and Brief Psychiatric Rating Scale (Berman et al.,
2000). This was the first clinical study to demonstrate that selective glutamatergic drugs may be
effective for the treatment of MDD.
One limitation of the Berman et al. (2000) study was the limited three day follow-up
period. In that study, the ketamine treatment group did not return baseline depression scores
during the follow-up period, which makes it difficult to determine the duration of the
antidepressant effects of ketamine. Thus, Zarate and colleagues conducted a clinical study to
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assess the antidepressant effects of ketamine in treatment-resistant depression and to determine a
better understanding of the duration of the antidepressant effects. Following a single 0.5 mg/kg
intravenous infusion of ketamine, treatment-resistant patients showed a significant reduction in
depression scores at 110 min that lasted up to 7 days (Zarate et al., 2006). Specifically, 71% of
the patients achieved response criteria one day after the fusion, while 29% achieved full
remission. Additionally, 35% maintained response criteria on day seven (Zarate et al., 2006).
Again, the hallucinogenic (or euphoric) effects diminished before the onset of the antidepressant
effects of ketamine. This study confirmed the finding in the Berman et al. (2000) study that
ketamine produces rapid and prolonged antidepressant effects in the treatment of depression.
Two studies have evaluated the effects of repeated ketamine infusion in patients suffering
from treatment-resistant depression to determine if repeating dosing could extend the
antidepressant effects of ketamine beyond seven days. In both studies, patients received up to six
ketamine infusions over approximately 12 days. One study found that the average relapse rate
was 19 days after the sixth and final ketamine infusion, with one patient remaining depression
free for more than three months (ann het Rot et al., 2010). In the second study, ketamine
infusions produced an antidepressant effect in 70.8% of the patients and these antidepressant
effects lasted for a median of 18 days (four participants did not relapse by the last follow up day
[83 days]) (Murrough et al., 2013). Both of these studies reported safety and tolerability similar
to that seem with the single ketamine infusion studies.
A multi-site large scale clinical study compared the effects of a single low dose of
ketamine (0.5 mg/kg, i.v.) to an active placebo, the anesthetic benzodiazepine midazolam (0.045
mg/kg, i.v.), in treatment-resistant patients. Following drug infusion, the ketamine group showed
a 64% response rate at 24 hours and 46% response rate on day seven; whereas, the midazolam
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group showed a response rate of 28% at 24 hours and 18% on day seven (Murrough et al., 2013).
These results suggested that the antidepressant effects of ketamine are not a result of its
anesthetic properties. A second study compared the effects of ketamine and ECT in patients
suffering from MDD. This study found that both ketamine and ECT produced antidepressant
effects; however, ketamine produced superior antidepressant effects in terms of response onset.
For example, ketamine produced rapid antidepressant effects starting at 24 hours; whereas, the
antidepressant effects of ECT were not expressed until day two. By day three, both ketamine and
ECT were equally efficacious (Ghasemi et al., 2014). These results suggest that ketamine is as
efficacious, if not more efficacious, as ECT for treating MDD.
There are several stages to the drug development process, and safety and ethical concerns
limit human research early in the drug development process. Animal (or preclinical) research
plays an important role in the drug development process and allows the research to have greater
control over the experimental conditions. Researchers have worked to develop preclinical assays,
both behavioral and molecular, to screen novel drugs for their clinical implications. Most
behavioral assays used to screen antidepressant drugs have face, predictive, and/or construct
validity, and some behavioral models will have more than one type of validity. For example, the
chronic unpredictable stress is a procedure in which animals are exposed to mild stressors (e.g.
food deprivation, dirty cages, temperature changes, etc.) for 21 or more days and several
behavioral measures are assessed (e.g. latency to feed, sucrose preference, etc.). Chronic
unpredictable stress is a preclinical procedure that has high face validity because the animals are
exposed to chronic stressors and show a decrease in behaviors that would be considered
pleasurable (e.g. sucrose consumption, etc.). Additionally, this procedure has predictive validity
because it takes chronic (not acute) administration of antidepressant drugs to restore behavior,
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which is similar to findings in humans with depression. Most researchers will use a variety of
preclinical procedures as tools for assessing the effects and clinical implications of novel drugs.
Ketamine has been shown to produce antidepressant-like effects in several preclinical
models of depression: forced swim test, tail suspension test, learned helplessness, and chronic
unpredictable stress. For example, ketamine reduces immobility time in the forced swim test
(Engin, Treit, & Dickson, 2009; Gigliucci et al., 2013). Additionally, ketamine reverses
corticosterone-induced changes in the forced swim test, which is used to model treatmentresistant depression (Koike, Iijima, & Chaki, 2013). Furthermore, acute and chronic ketamine
treatment has been shown to reverse physiological-induced changes in body weight, adrenal
gland weight, and corticosterone and adrenocorticotropic hormone concentrations following 40
days of chronic mild stress (Garcia et al., 2009). Also consistent with clinical data, ketamine
produces rapid antidepressant-like effects following repeated shocks in the learned helplessness
paradigm after a single injection, while repeated dosing with monoaminergic antidepressant
drugs is required to product antidepressant-like effects (Maeng et al., 2007; Koike et al., 2011).
Furthermore, these antidepressant-like effects of ketamine have been shown to last 7-14 days in
the forced swim test (Maeng et al., 2007; Autry et al., 2011; Tizabi et al., 2012), chronic
unpredictable stress paradigm (Li et al., 2011), and tail suspension test (Koike et al., 2011).
Differential-Reinforcement-of-low-Rate 72 s Operant Procedure
The different-reinforcement-of-low-rate (DRL) 72 sec operant procedure has been used
since the 1980s to selectively screen novel and established antidepressant ligands including
tricyclic, SSRIs, SNRI, and MAO inhibitors (McGuire and Seiden, 1980; O’Donnell, Marek, &
Seiden, 2005; O'Donnell and Seiden, 1982; O'Donnell and Seiden, 1983). Under the DRL
schedule, animals are trained to wait a specific interresponse time (e.g. 72 sec) between lever
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responses in order to receive a reinforcer and drugs with clinical efficacy as antidepressants have
been shown to reliably increase the number of reinforcers received, usually decrease the number
of responses emitted, and produce a rightward shift in the peak location of the interresponse time
(IRT) distribution. McGuire and Seiden (1980) found dissociable effects of the tricyclic
antidepressant imipramine in rats responding on a DRL 9 s schedule as compared to rats
responding on a DRL 72 s schedule. Imipramine did not exert an effect on reinforcement rate or
response rate under the DRL 9 s schedule; whereas, it produced a significant increase in
reinforcement rate and decreased response rate under the DRL 72 s schedule. In a follow up
study, the MAO inhibitors isocarboxazid, iproniazid, and phenelzine increased reinforcement
rate and decreased response rate; whereas, alcohol only decreased response rate and morphine
exerted no effects on DRL responding (O’Donnell & Seiden, 1982). Additionally, SSRIs
produce the same behavioral effects as tricyclics and MAO inhibitors by increasing
reinforcement rate and decreasing response rate (Sokolowski & Seiden, 1999).
The underlying factors responsible for antidepressant efficacy in the DRL task are
unknown; however, O’Donnell et al. (2005) suggest three hypotheses. The first is that the effects
of antidepressant drugs on DRL performance may be related to the animals’ ability to make a
temporal discrimination. The second hypothesis is that antidepressant drugs may selectively
decrease ‘impulsiveness’ in the animals. The third hypothesis is that animals are trained and
tested while under food or water deprivation (which is often used as an environmental stressor)
and antidepressant drugs may improve response efficacy by reducing interactions between
temporal discrimination or impulsivity and the stress of the behavioral contingencies in the DRL
procedure.
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In contrast, the pharmacology of the DRL 72 sec operant procedure is better understood.
The DRL 72 sec procedure has high predictive validity for screening antidepressant drugs, as
other drug classes (e.g. opioids, benzodiazepines, and amphetamines) do not produce the same
behavioral profile as antidepressant drugs (for review see O’Donnell et al., 2005). For example,
amphetamine and caffeine decrease reinforcement rate and increase response rate under the DRL
72 s procedure (Richard, Sabol, & Seiden, 1993; Marek et al., 1993; van Hest, van Drimmelen,
& Olivier, 1992); whereas, alcohol and pentobarbital decrease response rate and reinforcement
rate, respectively (O’Donnell & Seiden, 1982). Furthermore, the DRL 72 sec procedure is not
vulnerable to the false positives of psychostimulants, which is an issue with the forced swim test.
For example, caffeine has been shown to produce increased locomotor activity (Paterson et al.,
2010), but it also produces antidepressant-like effects in the forced swim test (Sunal et al., 1994).
However, caffeine does not produce antidepressant-like effects in the DRL 72 s procedure
(Marek et al., 1993). Furthermore, the DRL 72 s has some face validity because the animals are
single housed (or isolated) for the duration of training and testing. Also, the animals are food
restricted, and food restriction is stressor commonly used in the chronic unpredictable stress
procedure.
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Table 6.
Effects of antidepressant, glutamatergic, and abused drugs in the DRL 72 s procedure
Drug Pharmacology
Tricyclic
antidepressants
(Imipramine,
Desipramine,
Nortriptyline)
MAO inhibitors
(Iproniazid,
Isocarboxazid)
SSRIs
(Fluoxetine,
Sertraline,
Paroxetine,
Fluvoxamine)
Atypical
Antidepressants
Bupropion
Glutamatergic
drugs
MK-801
LY-341495
(mGluR2/3
antagonist)
MTEP (mGluR5
antagonist)
Other Drugs
Alcohol
Morphine
Pentobarbital
Caffeine
Amphetamine

Strain/Sex

Reinforcement Responses
rate
rate

Interresponse
Time (IRT)

Reference
Dekeyne et al. 2002;
Marek et al. 1988;
O’Donnell et al.
1983; Paterson et al.
2010*; Richards et
al. 1993;

S-D/males

↑

↓

→, NC

S-D/males

↑

↓

→

O’Donnell et al. 1982

S-D/males

↑

↓, NC

→, NC

Dekeyne et al.
2002*; Sokolowski
et al. 1999*; Paterson
et al. 2010; Marek et
al. 1989a; Seiden et
al. 1985

S-D/males

↓, NC

↑, NC

←, NC

S-D/males
S-D/males

↓
NC

↑
NC

←
Not Analyzed

S-D/males

↑

↓

Not Analyzed

S-D/males
S-D/males
S-D/males
S-D/males
S-D/males

NC
NC
↓
↓
↓

↓
NC
NC
↑
↑

Not Analyzed
Not Analyzed
Not Analyzed
←
←

Dekeyne et al.
2002*;Paterson et al.
2010; Seiden et al.
1985

Ardayfio et al. 2008
Bespalov et al. 2008

Molina-Hernandez et
al., 2006
O’Donnell et al. 1982
O’Donnell et al. 1982
O’Donnell et al. 1982
Marek et al. 1993
Van Hest et al. 1992;
Richards et al. 1993

S-D, Sprague-Dawley; ↑, increase; ↓, decrease; →, rightward shift; ←, leftward shift; NC, No
Change
* indicate articles that produced no change (NC)
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Table 6.
Effects of glutamatergic drugs on ICSS

Drug
Pharmacology
Noncompetitive
NMDA antagonist
Ketamine

Strain/Sex

ICSS Procedure

Effect

References

L-H/male

VI-10s

Mixed ↑↓

Herberg et al. 1989

MK-801

L-H/male
S-D/male
S-D/male

VI-10s
Rate
Frequency-rate/VI-3s

Herberg et al. 1989
Olds, 1996
Sundstrom et al. 2002

Wistar/male

Discrete Trial

Mixed ↑↓
↑ rate
↓T-LR,
-Max rate
↓CIT, ↑L

L-E/male

Frequency-rate

S-D/male
Fisher/male

FI-60s
Discrete Trial

↓T-LR,θ-0
↓Max rate
-rate
↓CIT

Wistar/male

Discrete Trial

↑CIT, ↑L

Bespalov et al. 2006

Wistar/male

Discrete Trial

-CIT, -L

Kenny et al. 2003

Wistar/male

Discrete Trial

-CIT, -L

Bespalov et al. 2006

Wistar/male

Discrete Trial

-CIT, ↑L

Bespalov et al. 2006

Wistar/male
Wistar/male

Discrete Trial
Discrete Trial

↑CIT, -L
-CIT, ↑L

Kenny et al. 2003
Bespalov et al. 2006

Phencyclidine

Competitive
NMDA antagonist
D-CPPene
AMPA antagonist
NBQX
GYKI-53655
Glycine site
antagonist
L-701,324
mGluR5 antagonist
MPEP

Bespalov et al. 2006;
Kenny et al. 2003
Carlezon et al. 1993
Schaefer et al. 1990
Kornetsky et al. 1979

mGluR2 agonist
LY314582
Wistar/male Discrete Trial
-CIT, -L
Kenny et al. 2003
mGluR2 antagonist
LY341495
Wistar/male Discrete Trial
-CIT, -L
Kenny et al. 2003
S-D, Sprague-Dawley; L-H, Lister Hooded; L-E, Long Evans; VI, Variable Interval; FI, Fixed
Interval; ↑, increase; ↓, decrease; T-LR, Threshold-Locus of Rise; CIT, Current Intensity
Threshold; θ, Theta; L, Latency
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Intracranial Self-Stimulation Operant Procedure
The abuse related effects of ketamine have been evaluated in a number of preclinical
procedures including self-administration, drug discrimination, and conditioned place preference.
Ketamine has been shown to maintain self-administration in rhesus monkeys (Broadbear,
Winger, & Woods, 2004; Moreton, Meisch, Stark, & Thompson, 1977; Young & Woods, 1981)
and rats (de la Peña et al., 2012; Rocha, Ward, Lytle, & Emmett-Oglesby, 1996). Moreover,
ketamine has been shown to produce cross generalization to other noncompetitive NMDA
antagonists, such as PCP and MK-801, in drug discrimination studies (DeVry & Jentzsch, 2003;
Grant, Colombo, Grant, & Rogawski, 1996; Killinger, Peet, & Baker, 2010; Overton, Shen, Ke,
& Gazdick, 1989; Rocha et al., 1996) and produces a place preference in the conditioned place
preference model (de la Peña et al., 2012; Suzuki et al., 2000). It is important to note that some
rats have failed to self-administer ketamine or to acquire the discriminative stimulus of ketamine
(Rocha et al., 1996). There is very limited research on the abuse-related effects of ketamine as
assessed using intracranial self-stimulation (ICSS) (Herberg & Rose, 1989).
Olds and Milner (1954) were the first to report the rewarding properties of ICSS in which
rats with electrodes implanted in the septal area of the brain would press a lever for electrical
stimulation. Intracranial self-stimulation (ICSS) is one approach used to assess and compare
abuse liability of drugs (Carlezon and Chartoff, 2007; Kornetsky & Esposito, McLean, &
Jacobson, 1979; Wise, 1996). For ICSS in general, animals are trained to lever press for brain
stimulation delivered via electrodes implanted in brain regions such as the medial forebrain
bundle. Electrical stimulation of the medial forebrain bundle depolarizes descending myelinated
axonal fibers that project to and synapse on dopaminergic neurons in the ventral tegmental area.
In turn, the ventral tegmental area activates the ascending mesolimbic pathway, specifically the
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nucleus accumbens (Wise, 1996). Over the years, a number of ICSS procedures have been
established to assess the abuse related effects of drugs such as rate, discrete trail current
intensity, and frequency rate procedures.
In “frequency-rate” ICSS procedures, different frequencies of brain stimulation are used
to engender frequency-dependent increases in ICSS rates and thereby establish a wide range of
baseline ICSS rates. This type of procedure is useful in part because of its sensitivity to detect
drug effects on both low and high rates of operant responding. Many drugs of abuse, and
especially stimulants like cocaine and amphetamine, increase low ICSS rates maintained by low
brain-stimulation frequencies, and this “facilitation” of ICSS is often interpreted as an abuserelated effect (Vlachou and Markou, 2011; Bauer et al., 2013b). For example, amphetamine,
methamphetamine, cocaine, and methcathinone (an active and common constituent in “bath
salts”) exclusively increase low ICSS rates in the frequency-rate ICSS procedures (Bauer, Banks,
Blough, & Negus, 2013a; Bauer, Banks, Negus, 2014; Bonano, Glennon, De Felice, Banks, &
Negus, 2014). Most antidepressant drugs decrease high rates of behavior maintained at high
frequencies of brain stimulation in the frequency-rate ICSS procedure (Rosenberg, Carroll, &
Negus, 2013). For example, the tricyclic antidepressant drugs clomipramine and nortriptyline
decreased ICSS across a board range of high and intermediate stimulation frequencies, while the
SSRI citalopram decreased ICSS rates only at high frequencies (Rosenberg et al., 2013).
The noncompetitive NMDA receptor antagonists phencyclidine and MK-801 have been
evaluated under a number of ICSS parameters including frequency-rate ICSS. For example,
phencyclidine and MK-801 increase low ICSS rates that are maintained at low brain-stimulation
frequencies with minimal effects exerted on high ICSS rates maintained at high brain-stimulation
frequencies (Carlezon and Wise, 1993; Corbett, 1989; Sundstrom et al., 2002; Wise, Bauco, &
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Carlezon, 1992). The effects of other glutamatergic compounds also have been evaluated on
ICSS; however, none of these drugs have been shown to produce abuse-related effects (see table
6). The only study that has examined the effects of ketamine on ICSS used a fixed frequency and
intensity of brain stimulation under a variable interval 10 s schedule and rates were assessed in
10-min bins for 60 min (Herberg and Rose, 1989). That study found that 3.0 mg/kg ketamine
increased mean ICSS rates in the 10-20 and 40-50 min time bins, but did not effect ICSS rates
during the other time bins. Thus, these rate increases were small and inconsistent across the test
session. Additionally, higher ketamine doses (10-100 mg/kg) decreased ICSS. Ketamine effects
on ICSS have yet to be fully elucidated and have not been reported in subjects responding under
a frequency-rate ICSS procedure.
Rationale for Experiment 1: Effects of Ketamine on Differential-Reinforcement-of-lowRate 72 s Responding in Rats
Experiment 1 sought to extend the preclinical evidence of the antidepressant-like effects
of ketamine using the DRL 72 s operant procedure and to determine if the DRL 72 s operant
procedure is suitable for evaluating the antidepressant effects of ketamine. In addition to testing
ketamine in the DRL 72 sec procedure, the present study tested the more selective and higher
affinity noncompetitive NMDA receptor antagonist MK-801, which is often used as a
comparator in other preclinical studies (Autry et al., 2011; Engin et al., 2009; Maeng et al., 2008)
and the NMDA receptor agonist NMDA for comparison. Finally, the selective serotonin reuptake
inhibitor (SSRI) fluoxetine and the tricyclic imipramine served as positive controls and the
psychostimulant d-amphetamine served as a negative control.
Rationale for Experiment 2: Effects of Acute and Repeated Ketamine on Intracranial SelfStimulation in Rats
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To address the issue of limited data on the abuse-related effects of ketamine using the
ICSS assay, Experiment 2 compared the effects of ketamine, MK-801, and phencyclidine on
ICSS using a frequency-rate procedure that has been used previously to evaluate the effects of
opioids (Altarifi and Negus, 2011; Altarifi, Rice, & Negus, 2013; Negus, Bilsky, Carmo, &
Stevenson, 2010; Negus et al., 2012), monoamine releasers and uptake inhibitors (Bauer et al.,
2013a,b; Bonano et al., 2013; Negus, O’Connell, Morrissey, Cheng, & Rice, 2012; Rosenberg et
al., 2013), and cannabinoids (Kwilasz and Negus, 2012). The present study evaluated the doseeffect and time-course of effects of ketamine, MK-801, and phencyclidine. Additional, studies
were conducted to examine the effects of repeated ketamine dosing using a testing strategy that
has been shown to produce tolerance to ICSS rate-decreasing effects and to enhance expression
of ICSS rate-increasing effects with mu opioid receptor agonists (Altarifi and Negus, 2011;
Altarifi et al., 2013).
Rationale for Experiment 3: Glutamatergic Antagonists and Involvement of Serotonin in
the Antidepressant-like Effects of Ketamine in the Differential-Reinforcement-of-low-Rate
72 s Operant Procedure
Experiment 3 was designed to evaluate the effects of other glutamatergic antagonists (i.e
NMDA and AMPA) and to determine the possible role of serotonin in the antidepressant-like
effects of ketamine using the DRL 72 s operant procedure. First, the NMDA antagonists
phencyclidine and memantine were tested because of their receptor binding profile. For example,
phencyclidine, from which ketamine is derived from, has a considerably higher binding affinity
for the NMDA receptor channel (Ki = 42.2 nM) as compared to ketamine (Ki = 1,190 nM), but
phencyclidine does not appear to be particularly selective for the NMDA receptor channel over
other receptors (Bresink et al., 1995; Roth et al., 2013). Similarly to ketamine, memantine has a
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relatively weak receptor binding affinity for the NMDA receptor channel (Ki = 690); however,
memantine is selective for NMDA receptor channels as it has no significant affinity for other
receptors (Bresink et al., 1995; National Institute of Mental Health's Psychoactive Drug
Screening Program, 2014). Additionally, the AMPA receptor antagonist NBQX was tested to
determine if NMDA receptor antagonism was responsible for the antidepressant-like effects of
ketamine, rather than non-specific blockade of glutamatergic activity.
Drug combination studies then were conducted to determine the role of serotonin
transporters and of serotonin 5-HT2 receptors in the antidepressant-like effects of ketamine in the
DRL 72 s procedure. Several studies have shown the involvement of serotonin in the behavioral
effects of ketamine (Fahim et al., 1973; Fukumoto et al., 2014; Yoshizawa et al., 2013). For
example, serotonergic mechanisms have been shown to mediate the antidepressant-like effects of
ketamine in both the forced swim test (Gigliucci et al., 2013) and the tail suspension test (Kos et
al., 2006). Most clinically available antidepressant drugs (e.g. tricyclics, SSRIs, and SNRIs)
share a common pharmacological mechanism, which is inhibiting serotonin transporters.
Ketamine has virtually no affinity for serotonin transporters (Ki = 161,700 nM) compared to
NMDA receptors (Ki = 1,190 nM); however, Martin et al. (1982) demonstrated that high doses
of ketamine inhibit the serotonin transporter in rats. The goal of experiment 3 was to determine if
the antidepressant-like effects ketamine in the DRL 72 s procedure are produced by inhibition of
serotonin transporters. The SSRI fluoxetine was used in combination with ketamine to evaluate
the role of inhibiting serotonin transporters in the antidepressant-like effects of ketamine.
The serotonin 5-HT2A receptor is an excitatory G-protein coupled receptor that is widely
distributed in both peripheral and central tissues and activation of 5-HT2A receptors stimulates
the release of the stress hormone adrenocorticotropic (ACTH) (Hoyer, Hannon, & Martin, 2002;
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Green, 2006). Additionally, 5-HT2A receptors act in opposition to postsynaptic 5-HT1A receptors,
which are inhibitory G-couple protein receptors that are located in cortical and hippocampal
areas and also regulate ACTH. Thus, antagonism of 5-HT2A receptors enhances activity of 5HT1A receptors (Hoyer et al., 2002; Lakoski & Aghajanian, 1985). Recently, 5-HT1A receptor
agonists have shown promise as potential antidepressant targets (Pehrson and Sanchez, 2014).
Ketamine has less binding at serotonin 5-HT2 receptors (Ki = 15,000 nM) as compared to
NMDA receptors (Ki = 1,190 nM); however, the functionality of ketamine at 5-HT2 receptors is
unknown (Kapur & Seeman, 2002). Additionally, ketamine treatment reverses corticosterone and
adrenocorticotropic hormone concentrations increases following 40 days of chronic mild stress
in rats (Garcia et al., 2009). Furthermore, atypical antipsychotic drugs, which primarily act as
serotonin 5-HT2 receptor antagonists at low doses, have been shown to be efficacious as
adjunctive treatment and display rapid effects for the remission of depressive symptoms as
compared to antidepressant drug treatment alone (Ostroff & Nelson, 1999; Tohen et al., 2010;
Wright et al., 2013). Lastly, the serotonin 5-HT2A antagonist M1009067 attenuates the
psychostimulant-like effects of MK-801 in the DRL 72 s procedure (Marek, Li, & Seiden,
1989b), indicating that the psychostimulant-like effects of MK-801 may be mediated through 5HT2A agonism. Ketamine and MK-801 produce opposing behavioral effects in the DRL 72 s
procedure (see Experiment 1 results), and thus, it is possible that the receptor actions of ketamine
and MK-801 are different at the 5-HT2A receptors. The goal of experiment 3 was to determine if
the antidepressant-like effects ketamine in the DRL 72 s procedure are mediated by 5-HT2A
antagonism. The serotonin 5-HT2 receptor antagonist ritanserin and serotonin 5-HT2 receptor
agonist quipazine were used to determine the role of serotonin 5-HT2 receptors in the
antidepressant-like effects of ketamine.
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Experiment 1: Effects of Ketamine on Differential-Reinforcement-of-low-Rat 72 s
Responding in Rats
Rationale
Experiment 1 sought to extend the preclinical evidence of the antidepressant-like effects
of ketamine using the DRL 72 s operant procedure. In addition to testing ketamine in the DRL 72
s procedure, the present study tested the more selective and higher affinity noncompetitive
NMDA receptor antagonist MK-801 and the NMDA receptor agonist NMDA for comparison.
Finally, the selective serotonin reuptake inhibitor (SSRI) fluoxetine and the tricyclic imipramine
served as positive controls and the psychostimulant d-amphetamine served as a negative control.
Experiment 1 Methods
Subjects
Twelve adult male Sprague-Dawley rats (Harlan Laboratories Inc, Frederick, MD)
weighing between 300 and 350 grams at the start of the experiment were used in this study. All
animals were housed individually in plastic cages (43.8 x 22.2 x 22.2 cm) in the vivarium with a
12-hr/12-hr light/dark cycle (lights on at 0600 hr) and all training and testing sessions were
conducted during the light portion of the cycle (0900 to 1600 hr). After one week of acclimation
to the vivarium, daily access to food (Teklad Lab Animal Diets, Harlan Laboratories Inc.) was
restricted in order to maintain the rats at 85% of their free feeding body weights; however, water
was freely available in the home cages. All experimental procedures were approved by the
Institutional Animal Care and Use Committee at Virginia Commonwealth University (IACUC
Protocol AM10215) and conducted in accordance with National Institutes of Health Guide for
the Care and Use of Laboratory Animals (Institute of Laboratory Animals Resources, 2011).
Apparatus
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Four operant conditioning chambers (29.2 x 30.5 x 24.1 cm) enclosed in sound
attenuating cubicles were used (Model ENV-008-VP, Med-Associates, St. Albans, VT). Each
chamber was equipped with a house light, ventilation fan, two retractable levers, and a food
trough. The house light was mounted on the middle panel of the back wall. On the front wall,
two retractable levers (4.5 cm wide, extended 2.0 cm through the center of one wall, 3 cm off the
floor) were mounted on either side of a food trough. The reinforcers were 45 mg purified diet
pellets (Product #F0021, Bio-Serv, Frenchtown, NJ). The fans mounted in the cubicles provided
background white noise. Programming of behavioral sessions and data collection were computer
controlled by Med-State software (Med PC, Version 4.1, Med-Associates) running on a
Windows XP operating system.
Drugs
The noncompetitive NMDA receptor antagonist (±) ketamine HCl (Sigma Aldrich, St.
Louis, MO), the NMDA receptor agonist N-Methyl-D-aspartic acid (gift from H Lundbeck A/S,
Copenhagen, Valby, Denmark), the tricyclic imipramine HCl (gift from A.H. Robins
Pharmaceuticals, Richmond, VA), the SSRI (±) fluoxetine HCl (NIMH Drug Repository,
Bethesda, MD, USA), the dopamine receptor agonist d-amphetamine sulfate salt (Sigma
Aldrich), and the noncompetitive NMDA receptor antagonist (+) MK-801 maleate (dizocilpine)
(Sigma Aldrich) were dissolved in 0.9% physiological saline. All drugs were administered
intraperitoneally at a volume of 1.0 ml/kg and doses represent the salt forms of the drugs.
Testing of each drug was completed before initiating testing with another drug. Doses and
pretreatment times were based on preliminary studies and previous studies in the literature
(O'Donnell and Seiden, 1983; Richards et al., 1993; Sokolowski and Seiden, 1999; Ardayfio et
al., 2008; Páleníček et al., 2011; Vunck et al., 2011). Drugs, doses, and pretreatment times were
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as follows: ketamine (1.0-10.0 mg/kg; 5 min), NMDA (3.0-30.0 mg/kg; 10 min), imipramine (110.0 mg/kg; 60 min), fluoxetine (2.5-10 mg/kg; 60 min), d-amphetamine (0.5-2.0 mg/kg; 20
min), and MK-801 (0.0125-0.1 mg/kg; 15 min). For the combination experiment, NMDA was
administered 5 min prior to ketamine. Ketamine and NMDA were administered in ascending
doses in order to determine the doses that had rate suppressant effects. The doses for imipramine,
fluoxetine, d-amphetamine, MK-801 and for the combination experiments with ketamine and
NMDA were administered using a Latin-square design.
Training Procedures
Magazine training. Drug-naïve rats were placed in the operant chamber in which the
house light was on, but the levers were not extended into the chamber. During the single
magazine training session, one reinforcer (i.e. food pellet) was delivered noncontingently
according to a fixed-time 60 s schedule for 30 min.
Lever press training. For the remaining training and test sessions the house light was on
and one lever was extended from the wall. During the next three sessions, rats were trained to
press either the left or right lever under a fixed-ratio 1 (FR 1) food-reinforcement schedule in
which each lever press resulted in delivery of a reinforcer. Sessions ended after delivery of 50
reinforcers or 60 min, whichever occurred first. The position of the lever associated with the FR
1 schedule was counter balanced with half of the rats assigned the right lever and half assigned to
the left lever. Following the completion of lever press training, all rats started DRL training.
DRL training. Under the DRL schedule, a response produced a reinforcer only after a
specified interresponse interval had elapsed. Responses emitted before the end of the
interresponse interval reset the timer and did not produce a reinforcer. The interresponse interval
was gradually increased from an initial value of 4.5 s to a terminal value of 72 s over 28 sessions.
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Rats were initially trained on a DRL 4.5 s schedule for 3 sessions. Next, the DRL schedule was
increased to 9 s for five sessions. The DRL schedule was then increased to 18 s for 10 sessions
and then to 36 s for 10 sessions. Finally, the DRL schedule was increased to the final schedule
value of 72 s until performance stabilized. DRL performance was considered stable when the
number of responses for each rat did not vary more than 10% of the mean for 5 of 6 consecutive
sessions. All DRL training and testing sessions were 60 min in length.
Testing Procedures
DRL testing. Once stable performance under the DRL 72 s schedule was established, test
sessions occurred twice weekly (typically Tuesday and Friday) with a minimum of one training
sessions prior to each test session. Testing of each drug was completed before initiating testing
with another drug, and a saline baseline was determined for each drug tested. Testing continued
until each drug had been tested in groups of 8-12 rats.
Statistical Analysis
The dependent variables included 1) total number of earned reinforcers during each test
session, 2) total number of responses during each test session, and 3) inter-response times (IRT)
for all responses during each test session. All data were expressed as means (+/- standard error of
the mean [S.E.M.]). Data during the test sessions were recorded in three 20 min time bins in
order to determine if drug treatment effects changed during the test sessions. Response and
reinforcer data were analyzed using a two-factor repeated measures analysis of variance
(ANOVA) with both drug dose and time bin treated as within-subjects factors. Only main effects
for the number of reinforcers, number of responses, and IRT distributions are reported for drugs
that failed to produce an interaction effect. Additionally, combination test data for ketamine and
NMDA were analyzed using one-way repeated measures ANOVA with drug dose as the factor.
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The IRT distributions were obtained by recording responses in 25 6-s bins, with the first 6 s bin
representing “burst responding”. To determine if there was a shift in the IRT distribution, a peak
location analysis was performed. Specifically, the median of the IRT distribution for each
individual rat was determined after eliminating burst responses from the total number of
responses. Medians (peak location) were analyzed using one-way repeated measures ANOVA
for dose (for more information on IRT analysis see Richards et al., 1993). For the IRT graphs,
the relative frequency for each 6 s bin was found for each rat (total number of responses divided
by number of responses for each time bin) and averages were calculated for each bin. When
interactions were significant, IRT distributions are shown for the 20 min time bins. Planned
multiple comparisons using Tukey post hoc tests were conducted after all significant ANOVAs,
as appropriate. The criterion for significance was p < 0.05. Data were analyzed using GraphPad
Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA).
Experiment 1 Results
DRL training and baseline performance. All 12 rats met the DRL training criterion in
a mean of 30.3 (± 3.2 SEM) training sessions. In order to determine if the saline baselines
changed during the study, data from the saline baselines for ketamine, MK-801, NMDA,
imipramine, fluoxetine and d-amphetamine were analyzed for the number of reinforcers and
number of responses with separate two-factor ANOVA’s (i.e. drug vehicle x time bin). These
analyses did not reveal any significant differences (p > 0.05), indicating that the saline baselines
did not significantly change for any of the drugs during the study.
Ketamine. For number of reinforcers (Figure 1a), the noncompetitive NMDA receptor
antagonist ketamine produced significant main effects for dose (F[4,44] = 25.68, p < 0.001) and
time bin (F[2, 22] = 5.00, p = 0.016), but the interaction was not significant (F[8,88] = 1.73, p =
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0.102). Compared to all other doses, 10.0 mg/kg ketamine significantly increased the number of
reinforcers during all three time bins (p < 0.001). Tukey post hoc tests also revealed that
significantly more reinforcers were obtained in the first 20-min time bin as compared to the third
20-min time bin (p < 0.05).
For number of responses (Figure 1b), ketamine produced a significant main effect of dose
(F[4,44] = 10.55, p < 0.001) and a significant interaction (F[8,88] = 6.63, p < 0.001). The main
effect for time bin was not significant (F[2,22] = 0.27, p = 0.763). As compared to all other
doses, 10.0 mg/kg ketamine significantly reduced the number of responses during both the first
(p < 0.001) and the second (p < 0.01) 20-min time bins, but not in the third, with the largest
decrease in responses occurring in the first 20-min time bin.
The top 3 panels in Figure 2 show the IRT distributions for ketamine for each 20-min
time bin. As compared to all other doses, 10.0 mg/kg ketamine produced a significant rightward
shift in the peak location of the IRT distribution in the first time bin (F[4,44] = 10.38, p < 0.001;
Figure 2a). The 10.0 mg/kg ketamine dose produced a significant rightward shift in the peak
location of the IRT distribution in the second time bin as compared to saline (F[4,44] = 5.65, p <
0.001; Figure 2b), but not in the third (F[4,44] = 1.71, p = 0.165; Figure 2c).
MK-801. For number of reinforcers (Figure 1c), the noncompetitive NMDA receptor
antagonist MK-801 produced significant main effects for dose (F[3,21] = 21.02, p < 0.001) and
time bin (F[2,14] = 6.95, p = 0.008), but the interaction was not significant (F[6,42] = 1.78, p =
0.126). Compared to saline, 0.05 and 0.1 mg/kg MK-801 produced significant decreases in the
number of reinforcers obtained throughout the test session (p < 0.001). For time bin, Tukey post
hoc tests revealed that significantly fewer reinforcers were obtained during the third time bin as
compared to the first 20-min time bin (p < 0.01).

42

For number of responses (Figure 1d), MK-801 produced a significant main effect for
dose (F[3,21] = 14.83, p < 0.001) and a significant interaction (F[6,42] = 2.86, p = 0.02); the
main effect for time bin was not significant (F[2,14] = 1.71, p = 0.217). Compared to all doses,
0.1 mg/kg MK-801 produced a significant increase in the number of responses in all 3 time bins,
with the greatest increase found in the second time bin (p < 0.01).
The middle 3 panels in Figure 2 show the IRT distributions for MK-801 for the 20-min
time bins. Compared to all other doses, 0.1 mg/kg MK-801 produced a significant leftward shift
in the peak location of IRT distribution in the first (F[3,21] = 12.09, p < 0.001; Figure 2d) and
second time bin (F[3,21] = 18.69, p < 0.001; Figure 2e). The 0.1 mg/kg MK-801 dose also
produced a significant leftward shift in the peak location of the IRT distribution in the third time
bin (F[3,21] = 11.97, p < 0.001; Figure 2f) as compared to saline.
NMDA. For number of reinforcers (Figure 1e), NMDA produced a significant main
effect for dose (F[3,30]=7.54, p < 0.001) and a significant interaction (F[6,60]=2.50, p = 0.031);
the main effect for time bin was not significant (F[2,20] = 2.73, p = 0.089). Compared to saline,
30.0 mg/kg NMDA produced a significant increase in the number of reinforcers obtained during
all 3 time bins, with the greatest increase found in the first time bin (p < 0.001).
For number of responses (Figure 1f), NMDA produced a significant main effect for dose
(F[3,30] = 9.85, p < 0.001) and a significant interaction (F[6,60] = 4.29, p < 0.001); the main
effect for time bin was not significant (F[2,20] = 1.87, p = 0.179). Compared to saline, 30.0
mg/kg NMDA produced a significant decrease in number of responses during both the first (p <
0.001) and third (p < 0.05) time bins, but not in the second time bin. The 30.0 mg/kg dose of
NMDA produced the greatest decrease in number of responses in the first time bin compared to
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Figure 1. Effects of ketamine (top; n = 12), MK-801 (center; n = 8), and NMDA (bottom; n =
11) on DRL 72 s performance. Left panels (a, c, e) show drug effects on number of reinforcers
earned. Abscissae: Time bin (20 min). Ordinates: Number of reinforcers. Right panels (b, d, f)
show drug effects on number of responses emitted. Abscissae: Time bin (20 min). Ordinates:
Number of responses. Drug doses are indicated in figure legend. Asterisks and plus signs directly
over the bars represent significant differences within the time bins. The lines show significant
differences across time bins. Main effects of dose have symbols on the figure legend. All data
were expressed as means ± S.E.M for 8-12 rats (ketamine, n = 12; MK-801, n = 8; NMDA, n =
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Figure 2. Effects of ketamine (top; n = 12), MK-801 (middle; n = 8), and NMDA (bottom; n =
11) on interresponse time (IRT) distribution for each of the three 20-min time bins. All panels
show drug effects on interresponse time (IRT) distributions. Abscissae: Interresponse time.
Ordinates: Relative frequency of responses. Drug doses are indicated in figure legend. Filled
points represent significant shifts in peak location after drug treatment as determined by peak
location analysis followed by a Tukey post hoc test, p < 0.05. All data were expressed as means
for 8-12 rats (ketamine, n = 12; MK-801, n = 8; NMDA, n = 11).
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the second and third time bins (p < 0.001), while the second time bin was not significantly
different from the third time bin.
The bottom 3 panels in Figure 2 show the IRT distributions for NMDA for each 20-min
time bin. Compared to saline, 30.0 mg/kg NMDA produced a significant rightward shift in the
peak location of the IRT distribution in the first time bin (F[3,30] = 5.18, p = 0.005; Figure 2g).
NMDA did not produce any significant changes to the peak location during the second (F[3,30]
= 2.70, p = 0.063; Figure 2h) or third (F[3,30] = 0.96, p = 0.424; Figure 2i) time bins.
The following drugs failed to produce a significant interaction effect for reinforcers,
responses, and IRT time bins; therefore, figure 3 presents only the main effects produced by drug
dose.
Imipramine. For number of reinforcers (Figure 3a), the tricyclic antidepressant
imipramine produced a significant main effect for dose (F[3,30] = 13.42, p < 0.001); however,
the main effect for time bin (F[2,20] = 0.03, p = 0.974) and the interaction were not significant
(F[6,60] = 1.26, p > 0.288). Imipramine dose-dependently increased the number of reinforcers
obtained throughout the test session. As compared to all doses, 10.0 mg/kg imipramine produced
a significant increase in the number of reinforcers obtained throughout the test session (p < 0.01).
Additionally, 3.0 mg/kg imipramine significantly increased the numbers of reinforcers
throughout the test session relative to saline (p < 0.05).
For number of responses (Figure 3b), imipramine produced significant main effects for
dose (F[3,30] = 13.03, p < 0.001) and time bin (F[2,20] = 9.80, p = 0.001); the interaction was
not significant (F[6,60] = 0.70, p = 0.647). As compared to all doses, 10.0 mg/kg imipramine
produced a significant decrease in the number of responses (p < 0.001). Additionally, 3.0 mg/kg
imipramine produced a significant decrease in the number of responses compared to saline (p <
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0.05). For time bin, Tukey post hoc tests revealed that significantly more responses were made in
the first (33.74 +/- 1.85) time bin compared to the second (29.86 +/- 1.42) and the third (29.75
+/- 1.82) time bins (p < 0.01). For IRT distributions (Figure 3c), 10.0 mg/kg imipramine
produced a significant rightward shift in the peak location as compared to saline (F[3,30] = 8.19,
p < 0.001).
Fluoxetine. For number of reinforcers (Figure 3d), the SSRI antidepressant fluoxetine
produced a significant main effect for dose (F[3,30] = 8.26, p < 0.001); the main effect for time
bin (F[2,20] = 1.01, p = 0.381) and the interaction were not significant (F[6,60] = 2.15, p =
0.06). As compared to saline, 10.0 mg/kg fluoxetine significantly increased the number of
reinforcers throughout the entire test session (p < 0.001).
For number of responses (Figure 3e), fluoxetine produced significant main effects for
both dose (F[3,30] = 5.76, p = 0.003) and time bin (F[2,20] = 4.57, p = 0.023); the interaction
was not significant (F[6,60] = 1.40, p = 0.228). Compared to saline, 10.0 mg/kg fluoxetine
significantly decreased the number of responses across the entire session (p < 0.01). For time bin,
Tukey post hoc tests revealed that significantly more responses were made in the first (32.92 +/01.76) time bin compared to the second (29.22 +/- 1.52) time bin (p < 0.05). Fluoxetine (2.5, 5.0,
and 10.0 mg/kg) produced a significant rightward shift in the peak location of the IRT
distribution (Figure 3f) as compared to saline (F[3,30] = 6.63, p = 0.001).
d-amphetamine. For number of reinforcers (Figure 3h), the indirect dopamine agonist damphetamine did not produce a significant main effect of dose (F[3,30] = 2.89, p = 0.052) or
time bin (F[2,20] = 2.83, p = 0.083), and the interaction was not significant (F[6,60] = 1.73, p =
0.129). For number of responses (Figure 3j), d-amphetamine produced a significant main effect
of dose (F[3,30] = 12.49, p < 0.001); the main effect of time bin (F[2,20] = 2.27, p = 0.129) and
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Figure 3. Effects of imipramine, fluoxetine, and d-amphetamine on DRL 72 s performance. Only
main effects are shown as these drugs failed to produce any significant interaction effects. Left
panels (a, d, h) show drug effects on number of reinforcers earned. Abscissae: Drug dose.
Ordinates: Number of reinforcers. Center panels (b, e, i) show drug effects on number of
responses emitted. Abscissae: Drug dose. Ordinates: Number of responses. Right panels (c, f, j)
show drug effects on interresponse time (IRT) distributions. Abscissae: Interresponse time.
Ordinates: Relative frequency of responses. Filled points represent significant shifts in peak
location after drug treatment as determined by peak location analysis followed by a Tukey post
hoc test, p < 0.05. Reinforcers and responses are expressed as means ± S.E.M for 11 rats. IRT
data are expressed as means. *p < 0.05, **p < 0.01, ***p < 0.001 versus saline; +p < 0.05 versus
all doses.
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the interaction were not significant (F[6,60] = 1.74, p = 0.126). All doses of d-amphetamine
significantly increased the number of responses across the entire test session (p < 0.05). Damphetamine produced a significant leftward shift in the peak location of the IRT distribution as
compared to saline (F[3,30] = 19.53, p < 0.001; Figure 3i).
Ketamine and NMDA combination testing. The dose-effect data revealed that both the
NMDA receptor antagonist ketamine and agonist NMDA produced similar antidepressant-like
effect in the DRL 72 sec operant procedure. To further examine this relationship, combination
tests were conducted to determine how these drugs may interact. In order to determine if NMDA
would potentiate (or antagonize) ketamine’s antidepressant-like effects, 10.0 and 30.0 mg/kg
doses of NMDA were co-administered with the 10.0 mg/kg dose of ketamine. As can be seen in
Figure 4 (a), the significant increase (F[3,24] = 6.57, p = 0.002) in the number of reinforcers
produced by 10.0 mg/kg ketamine was not potentiated or antagonized by either 10.0 or 30.0
mg/kg NMDA. Similarly, the significant decrease in the number of responses (F[3,24] = 13.37, p
< 0.001; Figure 4b) and the significant rightward shift in the peak location of the IRT
distributions (F[3,24] = 11.01, p < 0.001; Figure 4c) produced by 10.0 mg/kg ketamine were not
potentiated or antagonized by either dose of NMDA.
In order to determine if ketamine could potentiate (or antagonize) NMDA’s
antidepressant-like effects, the sub-effective dose of 3.0 mg/kg ketamine was co-administered
with 30.0 mg/kg NMDA (Figure 5). Interestingly, the 3.0 mg/kg dose of ketamine significantly
(p < 0.05) antagonized NMDA’s increase in the number of reinforcers (F[2,16] = 9.17, p <
0.001; Figure 5a) and was no longer significantly different form saline. However, the significant
rightward shift (F[2,16] = 8.32, p = 0.003) in the peak location of the IRT distributions (Figure
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5c) was not blocked. There were no significant changes in the number of responses (F[2,16] =
2.76, p = 0.093; Figure 5b).
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Figure 4. Effects of 10.0 mg/kg ketamine + NMDA combination DRL 72 s performance. Top
panel (a) show drug effects on number of reinforcers earned. Center panel (b) show drug effects
on number of responses emitted. Bottom panel (c) show drug effects on interresponse time (IRT)
distributions. Filled points represent significant shifts in peak location after drug treatment as
determined by peak location analysis followed by a Tukey post hoc test, p < 0.05. See figure 3
for further details. Reinforcers and responses were expressed as means ± S.E.M for nine rats.
IRT data expressed as means. *p < 0.05, **p < 0.01, ***p < 0.001 versus saline + saline.
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Figure 5. Effects of 30.0 mg/kg NMDA + ketamine combination DRL 72 s performance. Top
panel (a) show drug effects on number of reinforcers earned. Center panel (b) show drug effects
on number of responses emitted. Bottom panel (c) show drug effects on interresponse time (IRT)
distributions. Filled points represent significant shifts in peak location after drug treatment as
determined by peak location analysis followed by a Tukey post hoc test, p < 0.05. See figure 3
for further details. Reinforcers and responses were expressed as means ± S.E.M for nine rats.
IRT data expressed as means. ***p < 0.001 versus saline + saline. $p < 0.05 versus NMDA (30.0
mg/kg) + saline.
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Experiment 1 Discussion
To our knowledge this is the first study to examine the antidepressant-like effects of the
noncompetitive NMDA receptor antagonist ketamine in the DRL 72 sec procedure. Ketamine,
NMDA, imipramine, and fluoxetine all produced acute antidepressant-like effects by
significantly increasing the number of reinforcers, by decreasing the number of responses, and
by producing a rightward shift in the peak location of the IRT distribution. Conversely, damphetamine and MK-801 produced a significant increase in the number of responses, either
decreased (MK-801) the number of reinforcers, or produced no change (d-amphetamine), and
produced a leftward shift in the peak location of the IRT distribution. Moreover, ketamine was
found to attenuate the antidepressant-like effects of NMDA. None of the drugs tested produced
antidepressant-like effects 24 h post-injection (data not shown).
These results confirm that a relatively low (i.e. subanesthetic) dose of ketamine produces
antidepressant-like effects in the DRL-72 sec procedure and to a similar magnitude to that of the
clinically efficacious antidepressant drugs, imipramine and fluoxetine. Additionally, these results
support previous preclinical studies evaluating the antidepressant-like effects of ketamine. Most
current behavioral procedures used to screen antidepressant drugs (e.g. forced swim, tail
suspension, and DRL 72 sec) use acute dosing, such that animals are given a single injection
typically within one hour of the test session. In contrast, there are behavioral procedures (e.g.
chronic unpredictable stress and learned helplessness) that required repeated dosing of the
antidepressant drug before anhedonia-like behaviors are reversed. In the present study, ketamine
produced acute antidepressant-like effects, but failed to produce a prolonged antidepressant-like
effect in the DRL 72 sec procedure. A number of studies have failed to demonstrate prolonged
antidepressant-like effects with ketamine in the forced swim and tail suspension tests (Bechtholt-
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Gompf et al., 2011; Lindholm et al., 2011; Popik et al., 2008) or have only assessed the acute
antidepressant-effects of ketamine (Engin et al., 2009; Li et al., 2010; Yang et al., 2012). In
contrast, studies have shown that a single administration of ketamine can produce rapid and
prolonged effects in preclinical models. For example, Li et al. (2011) found that the same dose of
ketamine (10.0 mg/kg) used in the present study produced rapid reversal of deficits in anhedonialike behaviors following 21 days of chronic unpredictable stress in rats, while chronic treatment
is usually required for clinically efficacious antidepressant drugs. These ketamine effects
persisted for 7 days post-injection. Moreover, a number of studies have shown that the
antidepressant-like effects of ketamine can persist for up to a week in the forced swim test
(Maeng et al., 2008; Autry et al., 2011; Reus et al., 2011), tail suspension test (Koike et al.,
2011) and learned helplessness procedure (Maeng et al, 2008). It is important to note that there
several dose, species, and procedural differences across these studies that either found or failed
to find prolonged antidepressant-like effects with ketamine treatment and these differences may
account for the discrepant results.
Glutamatergic ligands have shown mixed results in the DRL procedure. For example, the
high-affinity noncompetitive NMDA receptor antagonist MK-801 produced psychostimulantlike effects (Ardayfio et al., 2008; and in the present study), the mGluR2/3 antagonist LY341495 had no effect on responding (Bespalov et al., 2008), and the mGluR5 antagonist MTEP
produced antidepressant-like effects (Molina-Hernandez et al., 2006). In the present study, all of
the glutamatergic drugs produced effects that changed during the test sessions. Ketamine and
NMDA produced similar effects by increasing reinforcers throughout the test sessions, while the
reduction in responses diminished over time. Interestingly, an ineffective dose of ketamine (3.0
mg/kg) significantly attenuated the antidepressant-like effects of NMDA (see Figure 5), rather
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than produce an additive effect as might have been predicted. Furthermore, NMDA (10.0 and
30.0 mg/kg) failed to enhance (or block) the antidepressant-like effects of ketamine (see Figure
4). One possible explanation for these findings is the effects of these drugs at the NMDA
receptor, specifically related to pharmacological action (agonist versus antagonist) and receptor
binding affinities/site location. For example, ketamine’s (Ki = 1,190 nM) binding affinity for the
NMDA receptor is almost 3-fold higher compared to NMDA (Ki = 3,900 nM) (Bresink et al.,
1995; Sakai et al., 2001), which would account for the ability for ketamine to block the
behavioral effects of NMDA and the inability of NMDA to block the behavioral effects of
ketamine. Furthermore, ketamine is a channel blocker that binds to the phencyclidine (PCP) site
inside the ion channel of the NMDA receptor (Bresink et al., 1995); whereas, NMDA binds to
the competitive glutamate site on the NMDA receptor (Sakai et al., 2001). Therefore, both of
these drugs can bind to the NMDA receptor simultaneously as they are not competing for the
same receptor site and, as a result, the pharmacological effects of ketamine could attenuate the
effects of NMDA by blocking ions from entering the cell through the ion channel of the NMDA
receptor.
Ketamine has been shown to produce a significant increase in glutamate release in the
prefrontal cortex at doses (10.0-30.0 mg/kg) that produce an antidepressant-like effect in a
variety of preclinical behavioral models, including the current DRL study (Moghaddam et al.,
1997; Lorrain et al., 2003;). Additionally, the glutamate dysfunction associated with MDD
appears to be bidirectional with evidence suggesting that there is a reduction of glutamatergic
activity. For example, researchers have found significantly lower concentrations of glutamate
and glycine in cerebral spinal fluid (Frye et al., 2007) and decreased concentrations of glutamine
and glycine in plasma (Altamura et al., 1993; Altamura et al., 1995). Moreover, the anterior
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cingulate cortex has been shown to have reduced glutamate and glutamine in adolescents (Mirza
et al., 2004) and adults (Auer et al., 2000) with severe depression. Preclinical data have shown
that the glycine-site partial agonist GLYX-13 produces antidepressant-like effects in the forced
swim test, novelty-induced hypophagia, and learned helplessness tests in rats (Burgdorf et al.,
2013). Furthermore, during clinical trials GLYX-13 produced rapid (~24 hours) and extended
(~7 days) antidepressant effect in treatment-resistant patients suffering from MDD (Moskal et
al., 2014). GLYX-13 is currently undergoing Phase II clinical trials (see clinicaltrials.gov at
http://www.clinicaltrials.gov/ct2/show/NCT01684163). Both clinical and preclinical findings,

suggest that some depressed patients may benefit from increasing glutamatergic activity.
Interestingly, the two NMDA receptor antagonists, ketamine and MK-801, produced
dissociable effects in the DRL 72 sec procedure with ketamine producing an antidepressant-like
effect and MK-801 producing a psychostimulant-like effect. The 10.0 mg/kg dose of ketamine
was found to increase reinforcers across all time bins, while responses were decreased in the first
two time bins, which corresponded with a rightward shift in the IRT distributions. Conversely,
the more selective NMDA receptor antagonist MK-801 (0.05 and 0.1 mg/kg) produced a
decrease in reinforcers across all time bins. Additionally, the 0.1 mg/kg MK-801 dose increased
responses and produced a leftward shift in the peak location IRT distribution across all time bins.
This finding is consistent with a previous report that found that MK-801 disrupted DRL 72 sec
performance (Ardayfio et al., 2008). The present study is not the first to show behavioral
differences between the NMDA receptor antagonists ketamine and MK-801. For example, at the
doses tested in the DRL procedure MK-801 produces hyperactivity in the open field locomotor
behavioral assay (Dravid et al., 2007; Engin et al., 2009; Wegener et al., 2011), while ketamine
does not alter locomotor activity (Engin et al., 2009; Koike et al., 2011; Réus et al., 2011; Yang
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et al., 2012). Furthermore, Autry et al. (2011) found that both ketamine and MK-801 produced
antidepressant-like effects in the forced swim test; however, the antidepressant-like effect of
ketamine lasted for one week, while the antidepressant-like effect of MK-801 lasted only 3
hours. Also, the mice treated with MK-801 in that study had nearly no time spent immobile - an
effect that may be attributed to MK-801’s hyperactivity effects and should be considered a false
positive response in the forced swim test.
The behavioral differences between ketamine and MK-801 may be a consequence of
differences in these two drugs’ receptor binding affinities and receptor selectivity (see Table 5).
Compared to MK-801, ketamine is 260 to 500-fold less selective for the PCP binding site on
NMDA ion channels depending on the brain region (Bresink et al., 1995; Tikhonova et al.,
2004). Seeman et al. (2005) found similar results (183 fold difference) when comparing binding
affinities in human cloned dopamine D2 receptors with ketamine having a significantly lower
binding affinity as compared to MK-801. Furthermore, ketamine has modest selectivity for the
NMDA receptor over other receptors. For example, ketamine has receptor affinities for
norepinephrine, dopamine, and serotonin transporters (Nishimura et al., 1998), opiate receptors
(i.e. mu, delta, and kappa), sigma receptors (Smith et al., 1987), and muscarinic receptors (Hirota
et al. 2002). This modest receptor selectivity and dissociable behavioral difference compared to
the higher affinity and more selective NMDA receptor antagonists MK-801 suggests that
ketamine is producing pharmacological effects on other receptors at doses that affect NMDA
receptors (see table 5 for binding affinities). While many studies (for example, Autry et al., 2011;
Li et al., 2010; Li et al., 2011) are evaluating the glutamatergic (e.g. AMPA and NMDA) or
downstream (e.g. the mammalian target of rapamycin) mechanisms underlying ketamine's
antidepressant effects, it is also important to evaluate non-glutamatergic mechanisms. For
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example, Yang et al. (2012) found that the weak mu opiate receptor agonist tramadol increased
the antidepressant-like effects of ketamine in the forced swim test, which may indicate the role of
mu receptor agonism in the antidepressant effects of ketamine.
In conclusion, the results from the experiment 1 add to the growing body of literature that
ketamine produces antidepressant-like effects preclinically. Further, our findings indicate that the
underlying mechanisms responsible for the clinical antidepressant effects of ketamine may not be
driven solely through NMDA receptor antagonism. The more selective and higher affinity
NMDA receptor antagonist MK-801 failed to produce an antidepressant-like profile in the DRL
72 sec procedure, suggesting that the diverse pharmacological profile of ketamine may play a
significant role in its antidepressant effects. Additionally, we have shown that the DRL 72 sec
model is appropriate for assessing the antidepressant-like effects of ketamine and can be used to
assess the underlying receptor mechanisms responsible for its antidepressant effects. Further
studies are needed to evaluate specific glutamatergic and non-glutamatergic mechanisms
responsible for these effects using the DRL 72 sec assay, as it appears to be more sensitive to the
false positives of psychostimulants seen in the force swim test (i.e. MK-801).
Experiment 2: Effects of Acute and Repeated Ketamine on Intracranial Self-Stimulation in
Rats
Rationale
Experiment 2 evaluated the dose-effect and time-course of effects of ketamine, MK-801,
and phencyclidine using on ICSS using a frequency-rate procedure. Additionally, follow-up
studies were conducted to examine effects of repeated ketamine dosing using a testing strategy
that produced tolerance to ICSS rate-decreasing effects and enhanced expression of ICSS rate-
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increasing effects with mu opioid receptor agonists (Altarifi and Negus, 2011; Altarifi et al.
2013).
Experiment 2 Methods
Subjects
Eleven adult male Sprague-Dawley rats (Harlan Laboratories Inc, Frederick, MD)
weighing between 300 and 350 grams at the start of the experiment were used in this study. All
animals were housed individually in plastic cages (32.4 x 19.7 x 19.7 cm) in the vivarium with a
12-hr/12-hr light/dark cycle (lights on at 0600 hr) and all training and testing sessions were
conducted during the light portion of the cycle (0900 to 1600 hr). All rats in the ICSS
experiments had free access to food and water expect during experimental sessions. All
experimental procedures were approved by the Institutional Animal Care and Use Committee at
Virginia Commonwealth University (IACUC Protocol AD2002) and conducted in accordance
with National Institutes of Health Guide for the Care and Use of Laboratory Animals (Institute
of Laboratory Animals Resources, 2011).
Surgery
Surgeries were only performed on rats in the ICSS experiments. Rats were anesthetized
with isoflurane gas (2.5–3% in oxygen; Webster Veterinary, Phoenix, Arizona, USA) for the
implantation of stainless-steel electrodes. The cathode of each bipolar electrode (Plastics One,
Roanoke, Virginia, USA) was 0.25 mm in diameter and covered with polyamide insulation,
except at the flattened tip. The anode was 0.124 mm in diameter and uninsulated. The cathode
was implanted in the left medial forebrain bundle at the level of the lateral hypothalamus (2.8
mm posterior and 1.7 mm lateral from the bregma, and 8.8 mm below the skull). The anode was
wrapped around one of three skull screws to serve as the ground, and the skull screws and
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electrode assembly were secured with orthodontic resin. Rats received ketoprofen (5 mg/kg i.p.
for 2 days) as a postoperative analgesic and were allowed to recover for at least 7 days before
commencing ICSS training.
Apparatus
ICSS experiments were conducted in twelve identical sound-attenuating chambers that
contained operant conditioning chambers (29.2 x 30.5 x 24.1 cm; Model ENV-007-VP-CT, Med
Associates) equipped with a single response lever (4.5 cm wide, extended 2.0 cm through the
center of one wall, 3 cm off the floor), stimulus lights (three lights colored red, yellow, and green
positioned 7.6 cm directly above the lever), a house light, and an ICSS stimulator (Model SG510; Med Associates). Electrodes were connected to the stimulator through bipolar cables and a
commutator (Model SL2C, Plastics One). Programming of behavioral sessions and data
collection were computer controlled by Med-State software (Med PC, Version 4.1, MedAssociates) running on a Windows XP operating system.
Drugs
The NMDA receptor antagonists (±) ketamine HCl (Sigma Aldrich), (+) MK-801
hydrogen maleate (dizocilpine) (Sigma Aldrich) and phencyclidine, and the monoamine reuptake
inhibitor cocaine HCl (provided by National Institute on Drug Abuse, National Institute of
Health, Bethesda, MD) were dissolved in 0.9% physiological saline. All drugs were administered
intraperitoneally at a volume of 1.0 ml/kg. Testing of each drug was completed before initiating
testing with another drug. Doses and pretreatment times were based on preliminary studies and
previous studies in the literature (Carlezon and Wise, 1993; Corbett, 1989; Herberg and Rose,
1989; Páleníček et al., 2011). Drugs, doses, and pretreatment times were as follows: ketamine
(3.2-18.0 mg/kg; 10 min), MK-801 (0.032-0.32 mg/kg; 15 min), phencyclidine (0.32-10.0
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mg/kg; 30 min), cocaine (10.0 mg/kg; 10 min). Dose order across rats was counterbalanced using
a Latin-square design.
Training Procedures
ICSS training. Rats were trained to press a lever under a FR 1 schedule of brain
stimulation using procedures similar to those described previously to study effects of
mu/kappa/delta opioid receptor agonists (Altarifi and Negus, 2011; Altarifi et al., 2013; Negus et
al., 2010), dopamine/norepinephrine/serotonin releasers and uptake inhibitors (Bauer et al.,
2013a,b; Bonano et al., 2013; Rosenberg et al., 2013) and cannabinoids (Kwilasz and Negus,
2012). During initial training sessions, which lasted 30-60 min, the house light was illuminated,
and each lever press produced electrical stimulation (0.5 s train of 0.1 ms square-wave cathodal
pulses) and illumination for 0.5 s of the colored stimulus lights over the lever. Responses during
the 0.5 s stimulation period did not produce additional stimulation. Initially, the frequency of
stimulation was held constant at 158 Hz, and the stimulation intensity for each rat was adjusted
gradually to the lowest value that would sustain a high rate of ICSS (≥30 stimulations/min).
Frequency manipulations were then introduced, and the terminal schedule consisted of sequential
10-min components. During each component, a descending series of 10 brain-stimulation
frequencies was presented, with a 60 s trial at each frequency. The frequency range extended
from 158 to 56 Hz in 0.05-log increments, and stimulation intensity was individually determined
during training and remained constant for each rat (range: 100-260 µA). Each frequency trial
began with a 10 s timeout, during which the house light was off and responding had no
scheduled consequences. During the last 5 s of this timeout, five noncontingent stimulations
were delivered once per second at the frequency available during that trial, and the lever lights
were illuminated during each stimulation. This noncontingent stimulation was then followed by a
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50 s “response” period, during which the house light was illuminated, and each lever press
produced electrical stimulation (0.5 s train of 0.1 ms square-wave cathodal pulses) and
illumination for 0.5 s of the colored stimulus lights over the lever. Training continued until rats
reliably responded at rates ≥50% maximum control rates (see Data Analysis) for at least three
and no more than six trials of all components for at least three consecutive days. Additionally,
rats were habituated to saline injections until these injections had significant no effect on ICSS
frequency-rate curves as determined by two-way analysis of variance (see Data Analysis).
Testing Procedures
Dose-effect experiments. Drug-naïve rats at the start of the experiment were used for
dose effect and time course studies. ICSS test sessions for dose-effect testing consisted of five
sequential components. The first component of each test session was considered an acclimation
component, and data from this component were discarded. Data from the second and third
“baseline” components were used to calculate control parameters of frequency-rate curves for
that test session in that rat (see Data Analysis). Immediately after completion of the baseline
components, a dose of test drug was administered intraperitoneally (i.p.), and after the designated
pretreatment time, ICSS was evaluated during two test components (10 min each, 20 min total).
Time course experiments. Additional studies also were conducted to investigate the
time course of effects. For these studies, baseline components were conducted as above. Rats
were then immediately injected with a dose of test drug, and pairs of ICSS test components was
initiated 10, 30, 100, and 300 min after the injection. Testing was conducted twice per week
(typically Tuesday and Friday). For both dose-effect and time-course experiments, testing was
initiated with different drugs in different rats and dose order was counterbalanced using a Latinsquare design. If ICSS performance remained stable in a given rat after completion of testing
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with the initial drug, then the rat was advanced to testing with other drugs or time course. Testing
continued until each drug had been tested in groups of 5-7 rats.
Repeated ketamine experiment. Initial dose effect and time course studies with acute
ketamine failed to reveal ketamine-induced increases in rates of ICSS maintained by any brain
stimulation frequency at any time. Consequently, follow-up studies were conducted in a drugnaïve group of 6 rats to examine effects of repeated dosing using a testing strategy that produced
tolerance to ICSS rate-decreasing effects and enhanced expression of ICSS rate-increasing
effects with mu opioid receptor agonists (Altarifi and Negus, 2011; Altarifi et al., 2013).
Training was conducted as described above, and once training and habituation to saline
injections were completed, “pre-drug baseline” sessions were conducted over a period of three
consecutive days to establish baseline ICSS performance before administration of ketamine.
Each pre-drug baseline session consisted of 3 components as described above. Testing proceeded
over a period of 26 days, with ICSS assessment beginning at 1600 hr each day (Figure 6). On
Days 0, 7, 14 and 21, ketamine was administered using a cumulative dosing regimen.
Specifically, test sessions consisted of three “baseline” ICSS components as described above,
followed by cumulative administration of ketamine at 30 min intervals, such that each sequential
ketamine dose increased the total cumulative dose by 0.25 log units. A pair of ICSS test
components was initiated 10 min after each sequential ketamine dose. The ketamine dose range
was 3.2-10 mg/kg on Day 0 and 3.2-18 mg/kg on Days 7, 14, and 21. Ketamine was also
administered on intervening days as follows: Days 1-6, 3.2 mg/kg/day; Days 8-13, 10
mg/kg/day; Days 15-20, 10 mg/kg twice per day (0900 hr and 1600 hr). On these intervening
days, three baseline ICSS components were conducted, the daily ketamine dose was
administered, and two test ICSS components were conducted beginning 10 min after ketamine.
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On Days 15-20, when 10 mg/kg ketamine was administered twice per day, one ketamine dose
was administered at 0900 hr without ICSS, and the second ketamine dose was administered at
1600 hr in the context of ICSS. On day 22, ketamine was not administered in the morning, and
the time course of effects produced by 18 mg/kg/day ketamine was determined at 0900 hr using
the time-course testing procedure described above. Ketamine treatment and ICSS testing were
omitted on days 23 and 24. On day 25, effects of 10 mg/kg cocaine were tested as a positive
control for drug-induced increases in ICSS. Specifically, three baseline components were
conducted as described above, followed first by i.p. administration of 10 mg/kg cocaine and then
10 min later by two ICSS test components.
Statistical Analysis
The primary dependent variable was the reinforcement rate in stimulations/trial during
each frequency trial. To normalize these raw data, reinforcement rates from each trial were
converted into the percent maximum control rate (% MCR). For dose-effect and time course
testing, the MCR was determined during the baseline components of each daily test session and
was defined as the mean of the maximal simulation rates observed in any frequency trial during
the second and third baseline components. Thus, % MCR for each trial was calculated as
(reinforcement rate during a frequency trial / MCR) x 100. Normalized data from the frequency
trials of consecutive test components were then averaged across rats for display and for statistical
analysis using two-way repeated measures analysis of variance (ANOVA), with drug dose or
time as one factor and ICSS frequency as the other factor. A significant ANOVA was followed
by a Holm–Sidak post-hoc test, and the criterion for significance was set at p < 0.05. To provide
an additional summary of ICSS performance, the total number of stimulations delivered across
all 10 frequency trials was determined for each component. The average number of total
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stimulations per test component was expressed as a percentage of the average number of total
stimulations per component during the second and third baseline components (% baseline).
Data from the study of repeated ketamine experiment were analyzed using a similar
approach, with the exception that baseline MCR and total stimulations were calculated from the
three-day pre-drug baseline components conducted before any ketamine administration (six total
pre-drug baseline components). Frequency-rate curves for each cumulative dose-effect were
examined by two-way repeated measures ANOVA with dose and frequency as the two factors.
In addition, baseline frequency-rate curves collected on Day 0 before initiation of ketamine
dosing were compared to baseline frequency-rate curves from Days 7, 14 and 21 to assess effects
of repeated ketamine exposure and ketamine withdrawal. Specifically, baseline ICSS
determinations on Days 7 and 14 represented 24 h withdrawal periods from the most recent dose
of six-day treatment with 3.2, and 10 mg/kg/day ketamine, respectively; baseline ICSS
determination on Day 21 represented a 7 h withdrawal period from the most recent dose of sixday treatment with 20 mg/kg/day.
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Figure 6. Shows the timeline of events for the repeated ketamine experiment. On days 0, 7, 14,
and 21 ketamine was administered using a cumulative dosing regimen. For cumulative dosing,
three baseline ICSS components were conducted, followed by cumulative administration of
ketamine (0.25 log unit increases) and a pair of ICSS test components were conducted 10 min
after each sequential ketamine dose. Ketamine was also administered on intervening days in the
same manner as dose effect test days. On day 22, the time course of effects for ketamine 18.0
mg/kg was determined. On day 23 and 24, ketamine treatment and ICSS testing were omitted.
On day 25, the effects of 10.0 mg/kg cocaine was determined as a positive control.
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Experiment 2 Results
Baseline performance. For the 11 rats used in dose-effect and time-course studies, the
mean ± SEM maximum control rate (MCR) was 56.64 ± 1.92 stimulations per trial, and the
mean total stimulations per component delivered across all frequencies was 253.45 ± 14.55.
Ketamine. Figure 7 shows the effects of ketamine, MK-801, and phencyclidine on ICSS.
After saline treatment, increasing frequencies of brain stimulation maintained increasing rates of
ICSS. Ketamine dose-dependently decreased ICSS. Ketamine produced a significant main effect
of frequency (F[9,54] = 75.06, p < 0.001), dose (F[3,18] = 15.40, p < 0.001) and significant
interaction (F[27,162] = 3.88, p < 0.001). The lowest dose of ketamine, 3.2 mg/kg, exerted no
effect on ICSS, but 5.6 mg/kg ketamine decreased ICSS at three intermediate frequencies (112141 Hz), and 10.0 mg/kg ketamine significantly decreased ICSS at the six highest frequencies
(79-158 Hz) (Figure 7a,b).
MK-801. MK-801 produced mixed rate-increasing and rate-decreasing effects that
depended on dose and brain stimulation frequency. MK-801 produced a significant main effect
of frequency (F[9,45] = 39.45, p < 0.001), dose (F[4,20] = 19.78, p < 0.001) and significant
interaction (F[36,180] = 7.58, p < 0.001). Thus, 0.032 mg/kg MK-801 did not alter ICSS, 0.1
mg/kg MK-801 increased ICSS at one intermediate frequency (89 Hz), and 0.18 mg/kg MK-801
produced a biphasic effect, increasing ICSS at low and intermediate frequencies (63-100 Hz) but
decreasing ICSS at the highest frequencies (141-158 Hz). The high dose of MK-801, 0.32 mg/kg,
significantly depressed ICSS at the five highest frequencies (100-158 Hz) (Figure 7c,d).
Phencyclidine. Phencyclidine produced both rate-increasing and rate-decreasing effects
that depended on dose, time, and brain stimulation frequency. Phencyclidine produced a
significant main effect of frequency (F[9,45] = 71.67, p < 0.001), dose (F[3,15] = 24.91, p <
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0.001) and significant interaction (F[27,135] = 6.34, p < 0.001). Doses of 1.0 and 5.6 mg/kg
phencyclidine exerted no effect on ICSS in the dose-effect study. The intermediate dose of
phencyclidine, 3.2 mg/kg, significantly increased ICSS at one frequency (100 Hz); whereas, the
high dose of phencyclidine, 10.0 mg/kg, significantly decreased ICSS at the five highest
frequencies (100-158 Hz) (Figure 7e,f).
Ketamine time course. Figure 8 shows the time course of effects produced by 5.6 and 10
mg/kg ketamine. Ketamine (5.6 mg/kg) produced a significant main effect of frequency (F[9,45]
= 42.43, p < 0.001), time (F[4,20] = 5.15, p = 0.005) and no significant interaction (F[36,180] =
1.28, p = 0.15). Treatment with 5.6 mg/kg ketamine had modest effects manifested as small but
significant decreases in ICSS after 10 min at 71 Hz, 30 min at 71 and 126 Hz, and 100 min at 7179 Hz (Figure 8a,b). Ketamine (10.0 mg/kg) produced a significant main effect of frequency
(F[9,54] = 97.14, p < 0.001), time (F[4,24] = 11.44, p < 0.001) and significant interaction
(F[36,216] = 3.27, p < 0.001). Treatment with 10.0 mg/kg ketamine produced greater decreases
in ICSS across a broader range of frequencies at 10, 30 and 100 min (Figure 8c,d). Neither dose
produced significant effects on ICSS after 300 min. ICSS was not increased at any frequency or
any time for either ketamine dose.
MK-801 time course. Figure 9 shows the time course of effects produced by 0.18 and
0.32 mg/kg MK-801. MK-801 (0.18 mg/kg) produced a significant main effect of frequency
(F[9,36] = 38.33, p < 0.001), time (F[4,16] = 11.50, p < 0.001) and no significant interaction
(F[36,144] = 1.64, p = 0.023). Treatment with 0.18 mg/kg MK-801 significantly increased
reinforcement rates at 10, 30, and 100 min across a broad range of brain stimulation frequencies
(63-126 Hz) (Figure 9a,b); this MK-801 dose did not produce rate-decreasing effects at any time
in the time-course study. MK-801 (0.32 mg/kg) produced a significant main effect of frequency
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(F[9,45] = 17.47, p < 0.001), time (F[4,20] = 3.90, p = 0.016) and significant interaction
(F[36,180] = 7.20, p < 0.001). Conversely, a higher dose of 0.32 mg/kg MK-801 depressed ICSS
after 10 and 30 min at high frequencies (100-156 Hz). At 100 min, 0.32 mg/kg MK-801
produced a biphasic effect, increasing reinforcement rats at 63 Hz, but decreasing reinforcement
rate at the highest frequencies (126-158). At 300 min, ICSS was still significantly depressed at
124-141 Hz (Figure 9c,d).
Phencyclidine time course. Figure 10 shows the time course of effects produced by 10.0
mg/kg phencyclidine. Phencyclidine (10.0 mg/kg) produced a significant main effect of
frequency (F[9,45] = 54.25, p < 0.001), time (F[4,20] = 12.20, p < 0.001) and a significant
interaction (F[36,180] = 9.83, p < 0.001). Treatment with 10.0 mg/kg phencyclidine produced a
significant decrease on ICSS rates at 10 and 30 min across a range of intermediate and high
frequencies (89-158 Hz); however, 10.0 mg/kg phencyclidine produced a significant increase on
ICSS rates at 100 (56-71 and 100 Hz) and 300 (63 Hz) min (Figure 10a,b).
Repeated ketamine on cumulative dose-effect curves. For the six rats used in the
repeated dosing ketamine experiment, the mean ± SEM maximum control rate (MCR) during
pre-drug baseline sessions was 57.00 ± 3.33 stimulations per trial, and the mean total
stimulations per component delivered across all frequencies was 276.75 ± 14.59. Under pre-drug
baseline conditions (i.e. before any ketamine administration), brain stimulation maintained a
frequency-dependent increase in ICSS rates. Figure 11 shows mean frequency-rate ICSS curves
for the pre-drug baseline determination before initiation of repeated ketamine treatment and
before ketamine testing on Days 0, 7, 14, and 21 of repeated ketamine treatment. Daily baseline
ICSS frequency-rate curves were not significantly affected by exposure to and withdrawal from
repeated ketamine: Significant main effect of frequency (F[9,45] = 75.73, p < 0.001), no
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significant effect of day (F[4,20] = 1.76, p = 0.176) and no significant interaction (F[36,180] =
1.29, p = 0.144).
Figure 12 shows the effects of cumulative ketamine on ICSS on Days 0, 7, 14, and 21 of
repeated daily ketamine treatment. On Day 0, before initiation of repeated ketamine, cumulative
ketamine (3.2-10.0 mg/kg) produced a dose-dependent decrease in ICSS (Figure 12a,b).
Specifically, 3.2 mg/kg ketamine did not alter ICSS, 5.6 mg/kg ketamine decreased ICSS at
frequencies of 89, 100 and 126 Hz, and 10.0 mg/kg ketamine decreased ICSS at 89-141 Hz.
Following repeated 3.2 mg/kg/day ketamine, cumulative doses of 5.6 and 10 mg/kg ketamine
decreased ICSS at fewer frequencies than initially, and a higher dose of 18 mg/kg ketamine was
introduced, which decreased ICSS at 100-158 Hz (Figure 12c,d). Following repeated 10
mg/kg/day ketamine (Figure 12e,f) and 20 mg/kg/day ketamine (Figure 12g,h), ICSS was not
altered by any cumulative dose of ketamine (3.2-18 mg/kg). Thus, during repeated ketamine
treatment, tolerance developed to the rate-decreasing effects of ketamine, but ICSS was not
increased by any ketamine dose at any frequency at any time. Statistical results for repeated
ketamine are as follows: Drug Naïve (Day 0): Significant main effect of frequency (F[9,45] =
70.40, p < 0.001), dose (F[3,15] = 3.41, p = 0.045) and no significant interaction (F[27,135] =
1.36, p = 0.127). Repeated 3.2 mg/kg/day (Day 7): Significant main effect of frequency (F[9,45]
= 52.31, p < 0.001), dose (F[4,20] = 12.51, p < 0.001) and significant interaction (F[36,180] =
2.38, p < 0.001). Repeated 10.0 mg/kg/day (Day 14): Significant main effect of frequency
(F[9,45] = 72.65, p < 0.001), no significant effect of dose (F[4,20] = 2.31, p = 0.093) and no
significant interaction (F[36,180] = 1.25, p = 0.173). Repeated 10.0 mg/kg/dayx2 (Day 21):
Significant main effect of frequency (F[9,45] = 106.30, p < 0.001), no significant effect of dose
(F[4,20] = 0.79, p = 0.546) and no significant interaction (F[36,180] = 0.85, p = 0.717).
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Figure 7. Dose-dependent effect of ketamine, MK-801, and phencyclidine on ICSS. Left panels
(a, c, e) show drug effects on full ICSS frequency-rate curves. Abscissae: Frequency of electrical
brain stimulation (Hz) (log scale). Ordinates: Percent maximum control reinforcement rate
(%MCR). Drug name and doses are indicated in legends. Filled points represent frequencies at
which ICSS rates after drug treatment were significantly different from vehicle rates as
determined by a two-way ANOVA followed by a Holm-Sidak post hoc test, p < 0.05. Right
panels (b, d, f) show summary ICSS data expressed as percent baseline total stimulations
delivered across all frequencies of brain stimulation per test component. Abscissae: Drug dose
(mg/kg). Ordinates: Percent baseline stimulations per test component. Upward/downward arrows
indicate significant drug-induced increase/decrease in ICSS relative to vehicle for at least one
brain stimulation frequency as determined by analysis of full frequency-rate curves in the left
panels. All data show mean ± SEM for six to seven rats (ketamine, n = 7; MK-801, n = 6;
phencyclidine, n = 6), except for 1.0 mg/kg ketamine data shown for five rats.
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Figure 8. Time course of effects produced by 5.6 and 10.0 mg/kg ketamine. Left panels (a, c)
show drug effects on full ICSS frequency-rate curves. Filled points represent frequencies at
which ICSS rates after drug treatment were significantly different from baseline rates as
determined by a two-way ANOVA followed by a Holm-Sidak post hoc test, p < 0.05. Right
panels (b, d) show summary ICSS data expressed as percent baseline total stimulations delivered
across all frequencies of brain stimulation per test component. Abscissae: Time (min). Ordinates:
Percent baseline stimulations per test component. Other details as in Figure 7. All data show
mean ± SEM for six to seven rats (5.6 mg/kg, n = 6; 10.0 mg/kg, n = 7).
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Figure 9. Time course of effects produced by 0.18 and 0.32 mg/kg MK-801. Left panels (a, c)
show drug effects on full ICSS frequency-rate curves. Filled points represent frequencies at
which ICSS rates after drug treatment were significantly different from baseline rates as
determined by a two-way ANOVA followed by a Holm-Sidak post hoc test, p < 0.05. Right
panels (b, d) show summary ICSS data expressed as percent baseline total stimulations delivered
across all frequencies of brain stimulation per test component. Other details as in Figures 7 and
8. All data show mean ± SEM for five to six rats (0.18 mg/kg, n = 5; 0.32 mg/kg, n = 6).
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Figure 10. Time course of effects produced by 10.0 mg/kg phencyclidine. Left panels (a) show
drug effects on full ICSS frequency-rate curves. Filled points represent frequencies at which
ICSS rates after drug treatment were significantly different from baseline rates as determined by
a two-way ANOVA followed by a Holm-Sidak post hoc test, p < 0.05. Right panels (b) show
summary ICSS data expressed as percent baseline total stimulations delivered across all
frequencies of brain stimulation per test component. Other details as in Figures 7 and 8. All data
show mean ± SEM for five to six rats.
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Figure 11. Baseline ICSS performance before initiation of repeated ketamine (Pre-drug Baseline)
and on Days 0, 7, 14, and 21 of repeated ketamine treatment. Data for Days 7 and 14 were
determined 23 h after the most recent ketamine dose. Data for Day 21 were collected 7 h after
the most recent ketamine dose. Filled points represent frequencies at which ICSS rates after drug
treatment were significantly different from baseline rates as determined by a two-way ANOVA
followed by a Holm-Sidak post hoc test, p < 0.05. Other details as in Figure 7. All data show
mean ± SEM for six rats.
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Figure 12. Effects of repeated ketamine on cumulative ketamine dose-effect curves. Cumulative
ketamine dose-effect curves were determined before repeated daily ketamine administration (a,
b), following six-days of 3.2 mg/kg/day ketamine (c, d), following six days of 10.0 mg/kg/day (e,
f), and following six-days of 10.0 mg/kg/day x 2 (twice a day, totaling 20.0 mg/kg/day) (g, h).
Left panels (a, c, e, g) show drug effects on full ICSS frequency-rate curves. Filled points
represent frequencies at which ICSS rates after drug treatment were significantly different from
baseline rates as determined by a two-way ANOVA followed by a Holm-Sidak post hoc test, p <
0.05. Right panels (b, d, f, h) show summary ICSS data expressed as percent baseline total
stimulations delivered across all frequencies of brain stimulation per test component. Other
details as in Figure 7. All data show mean ± SEM for six rats.
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Figure 13. Time course of effects produced by 18.0 mg/kg ketamine during repeated ketamine
administration on day 22. Left panels (a) show drug effects on full ICSS frequency-rate curves.
Filled points represent frequencies at which ICSS rates after drug treatment were significantly
different from baseline rates as determined by a two-way ANOVA followed by a Holm-Sidak
post hoc test, p < 0.05. Right panels (b) show summary ICSS data expressed as percent baseline
total stimulations delivered across all frequencies of brain stimulation per test component. Other
details as in Figures 7 and 8. All data show mean ± SEM for five to six rats.

76

B a s e lin e

125

1 0 .0 c o c a in e

%MCR

100
75
50
25
0
56

63

71

79

89

100 112 126 141 158

F re q u e n c y (H z )

Figure 14. Effects of 10.0 mg/kg cocaine following the termination of repeated ketamine on Day
25. The figure shows drug effects on full ICSS frequency-rate curves. Filled points represent
frequencies at which ICSS rates after drug treatment were significantly different from baseline
rates as determined by a two-way ANOVA followed by a Holm-Sidak post hoc test, p < 0.05.
Other details as in Figures 7. All data show mean ± SEM for six rats.
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On day 22, the time-course of effects produced by a bolus dose of 18.0 mg/kg ketamine
was determined. Treatment with 18.0 ketamine produced a significant main effect of frequency
(F[9,45] = 98.32, p < 0.001), dose (F[4,20] = 3.97, p = 0.016) and significant interaction
(F[36,180] = 2.39, p < 0.001). Significant decreases in ICSS were observed at 100-112 Hz from
30 to 300 min, but ICSS was not increased at any frequency at any time (Figure 13a,b). On Day
25, the effects of 10 mg/kg cocaine were examined as a positive control, and cocaine produced a
significant main effect of frequency (F[9,45] = 48.69, p < 0.001), dose (F[1,5] = 15.59, p =
0.011) and interaction (F[9,45] = 4.00, p < 0.001). Specifically, cocaine significantly facilitated
ICSS at brain stimulation frequencies of 63-100 Hz (Figure 14).
Experiment 2 Discussion
Experiment 2 used a frequency-rate ICSS procedure to compare abuse-related effects of
the noncompetitive NMDA antagonists ketamine and MK-801. There were two main findings.
First, the three compounds produced dissociable behavioral effects. Specifically, ketamine
produced only rate-decreasing effects, whereas, MK-801 and phencyclidine produced a mixed
profile of both rate-increasing and rate-decreasing effects. Second, repeated ketamine treatment
produced tolerance to the rate-decreasing effects of ketamine but failed to unmask abuse-related
facilitation of ICSS. Taken together, these findings suggest that effects of ketamine in ICSS may
be mediated by mechanisms other than or in addition to NMDA receptor antagonism. These
results also suggest that ketamine may be less likely than MK-801 and phencyclidine to produce
a stimulant-like profile of abuse-related effects, although failure of ketamine to facilitate ICSS
contrasts with other evidence for abuse liability of ketamine.
The present results are consistent with previous studies showing that MK-801 facilitated
ICSS in rats across a variety of reinforcement schedules and testing procedures. For example,
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MK-801 increased rates of ICSS maintained by fixed brain-stimulation frequencies and
intensities under FR 1 and variable-interval 10 sec schedules (Herberg and Rose, 1989; Olds,
1996). MK-801 also decreased brain-stimulation thresholds required to maintain ICSS in
procedures that manipulated either frequency of stimulation (Carlezon and Wise, 1993; Corbett,
1989; Sundstrom et al., 2002) or intensity of stimulation (Kenny et al., 2003; Bespalov et al.,
2006). The present study extends these earlier results by showing that MK-801 facilitated low
ICSS rates maintained by low brain-stimulation frequencies only at doses similar to or just below
those that also decreased higher ICSS rates maintained by higher brain-stimulation frequencies.
This mixed profile of rate-increasing and rate-decreasing effects distinguishes MK-801 from
effects of some other drugs, such as cocaine or amphetamine, that exclusively facilitate ICSS
across a broad dose range (Bauer et al., 2013b; Negus et al., 2012).
The ICSS results from the present experiment are consistent with previous studies
showing that phencyclidine increased rates and/or decreased threshold of ICSS maintained under
FR 1 schedule of reinforcement in ICSS procedures that manipulate frequency of brain
stimulation or intensity (Carlezon & Wise, 1993; Wise et al., 1992) or brain stimulation
(Kornestsky et al., 1979; Spielewoy & Markou, 2003). The present study extended previous
findings by testing a 10-fold dose range of phencyclidine and providing the time-course of
phencyclidine effects on ICSS. Specifically, an intermediate phencyclidine dose (3.2 mg/kg)
produced weak but exclusive facilitation of ICSS in the dose-effect study. The higher
phencyclidine dose initially depressed ICSS consistent with reduced response rates in the DRL
72 s procedure; however, ICSS facilitation was apparent at later time points (100-320 min) after
the behavioral disruption subsided. These phencyclidine effects are similar to the dose- and time-
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dependent facilitation of ICSS by MK-801, but contrast with the finding that ketamine only
depressed ICSS.
In contrast to MK-801 and phencyclidine, ketamine only depressed ICSS. This agrees
with a previous study that found more robust rate-increasing effects with MK-801 than with
ketamine in rats trained to respond for a fixed frequency and intensity of brain stimulation under
a variable interval 10 sec schedule (Herberg and Rose, 1989). That study evaluated ICSS rates in
10-min bins for 60 min. Rates were stable after vehicle treatment and 3.0 mg/kg ketamine
increased mean ICSS rates in the 10-20 and 40-50 min time bins. However, these increases were
small relative to effects of MK-801, ICSS rates were not affected at other time points by 3.0
mg/kg ketamine, and higher ketamine doses (10-100 mg/kg) only depressed ICSS as in the
present study. Additionally, the decrease of ICSS produced by ketamine is similar to the
decrease produced by tricyclic and SSRI antidepressant drugs (Rosenberg et al., 2013). Taken
together with the present results, these findings provide little evidence for facilitation of ICSS by
acute treatment with ketamine.
The effects of acute ketamine in the present study were superficially similar to effects of
acute treatment with mu opioid receptor agonists like morphine in opioid-naïve rats (Altarifi and
Negus, 2011; Altarifi et al., 2013). Thus, mu agonists also produced primarily ICSS depression
at early times after their administration. However, as initial rate-decreasing effects of mu
agonists dissipated in time-course studies, rate-increasing effects often emerged and
predominated at later times. Moreover, repeated morphine administration produced tolerance to
rate-decreasing effects of mu agonists and enhanced expression of rate-increasing effects. This
dependence of mu agonist ICSS effects on parameters of acute or repeated mu agonist exposure
suggested that ketamine effects may also depend on parameters of acute or repeated exposure.
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However, in contrast to morphine, ketamine failed to facilitate ICSS at any time after its acute
administration in the present study. Repeated ketamine produced tolerance to ketamine’s ratedecreasing effects, but again unlike morphine, repeated ketamine failed to unmask rateincreasing effects of ketamine, although cocaine did facilitate ICSS in these rats. Overall, then,
ketamine failed to facilitate ICSS under conditions that were sensitive to ICSS facilitation by
other drugs of abuse.
The frequency-rate ICSS procedure used in experiment 2 engendered a wide range of
baseline behavioral rates maintained by a wide range of brain-stimulation frequencies. Similarly
broad ranges of baseline behavioral rates can be maintained by food or other reinforcers by using
fixed-interval (FI) schedules of reinforcement, and one application of FI schedules in behavioral
pharmacology has been to study the degree to which drug effects on rates of operant responding
correlate with baseline response rates (Kelleher and Morse, 1968; Sanger and Blackman, 1976;
Branch, 1984). Given the potential role of rate-dependency as a determinant of drug effects, it is
notable that effects of MK-801, phencyclidine, and ketamine on varying rates of ICSS in the
present study are consistent with their effects on varying response rates maintained by other
reinforcers under FI schedules. For example, in rats responding for food under a multiple FR 30
FI 300 sec schedule, MK-801 increased low rates of responding maintained during early
segments of the fixed intervals, but decreased high rates of responding maintained during later
segments (McMillan et al., 1992). Furthermore, low and intermediate doses of phencyclidine
produced a modest increase of low rates in rats responding under a FI 90 s schedule, while high
doses of phencyclidine depressed responding (Wagner, Masters, & Tomie, 1984). These effects
are analogous to MK-801 and phencyclidine facilitation of low ICSS rates maintained by low
brain-stimulation frequencies, but depression of high rates maintained by high frequencies in the
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present study. In contrast to MK-801, McMillan et al. (1992) also found that ketamine only
decreased responding across all segments of the FI, similarly to ketamine’s exclusive ratedecreasing effects on ICSS in the present study. Ketamine also produced exclusively ratedecreasing effects in squirrel monkeys responding under a FI 8 min schedule of shock
presentation (Byrd, 1982).
Another operant conditioning schedule that engenders low rates of behavior is the
differential-reinforcement-of-low-rates (DRL) of responding procedure, which requires animals
to wait a specific time between operant responses to receive a reinforcer. MK-801 increases low
rates of behavior in rats responding under DRL 15 s and 72 s operant schedules (Ardayfio et al.,
2008; Hillhouse and Porter, 2014; Sanger, 1992; Stephens and Cole, 1996) and phencyclidine
increases response rates in rats maintained under a DRL 10 s and DRL 15 s (Hudzik & Slifer,
1992; Sanger, 1992; Sanger & Jackson, 1989); whereas, ketamine decreases rates of behavior in
rats responding on DRL 72 s schedule operant (Hillhouse and Porter, 2014). Taken together,
these studies demonstrate that low rates of operant responding are increased by MK-801 and
phencyclidine, but decreased by ketamine across a broad range of conditions. Similar results
have been obtained in procedures that measure locomotor activity. For example, at doses used in
this study, MK-801 and phencyclidine significantly increase relatively low rates of locomotor
activity in rats, whereas ketamine does not (Engin et al., 2009; Gilmour et al., 2009; Koike et al.,
2011; Réus et al., 2011; Wegner et al., 2011).
Ketamine and MK-801 have long been considered to share a common mechanism of
action as noncompetitive NMDA antagonists that vary primarily in terms of their potency. Drug
discrimination procedures have provided one source of behavioral data supportive of a shared
mechanism of action, and ketamine produces cross substitution with MK-801 and the other
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noncompetitive NMDA antagonist phencyclidine in drug discrimination procedures (DeVry and
Jentzsch, 2003; Grant et al., 2006; Killinger et al., 2010; Overton et al., 1989; Rocha et al.,
1996). However, MK-801 and ketamine, which produced the most dissociable effects on ICSS,
have remarkably different affinities at the noncompetitive NMDA binding site. For example, one
study found that MK-801 (Ki = 2.5 nM) was nearly 500-fold more potent for the noncompetitive
NMDA receptor site than ketamine (Ki = 1,190 nM) (Bresink et al., 1995). Moreover, ketamine’s
selectivity for NMDA receptors over other receptor types is modest (Hirota et al., 2002;
Nishimura et al., 1998; Seeman et al., 2005; Smith et al., 1987), suggesting that ketamine may
produce effects at targets other than NMDA receptors. The differential behavioral effects of
MK-801 and ketamine in the present study are consistent with different mechanisms of action of
these drugs to alter low rates of responding maintained by low frequencies of brain stimulation in
ICSS procedures or by other reinforcers in FI or DRL schedules of reinforcement. The identity
of these distinct mechanisms remains to be determined.
ICSS is often described as a behavioral procedure for preclinical assessment of abuse
liability and drug-induced facilitation of ICSS is often interpreted as an abuse-related effect
(Bauer et al., 2013b; Carlezon and Chartoff, 2007; Kornetsky et al., 1979; Vlachou and Markou,
2011; Wise, 1996). The effectiveness of MK-801 to facilitate ICSS in this and other studies is
consistent with its effectiveness to produce abuse-related effects in other preclinical procedures,
such as drug self-administration in nonhuman primates (Beardsley, Hayes, Balster, 1990; Koek
et al., 1988) and rats (Carlezon and Wise, 1996). Moreover, MK-801 produced a profile of
mixed rate-increasing and rate-decreasing effects, and we have suggested previously that such a
profile may be indicative of lower reinforcing effects relative to drugs like cocaine or
amphetamine, which produce exclusive facilitation of ICSS across a broad dose range (Bauer et
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al., 2013b; Negus et al., 2012a). In agreement with this possibility, drug self-administration data
suggest that NMDA antagonists may have weaker or less reliable reinforcing effects than
stimulants like cocaine (Beardsley et al., 1990; French, 1994; Marquis and Moreton, 1987).
However, the failure of ketamine to facilitate ICSS in the present study is not consistent with the
efficacy of ketamine to maintain self-administration in rats (de la Peña et al., 2012; Rocha et al.,
1996) and rhesus monkeys (Broadbear et al., 2004; Moreton et al., 1977; Young and Woods,
1981) or with epidemiological evidence for ketamine abuse cited in the introduction. Ketamine
sometimes fails to maintain self-administration in animals (De Luca and Badiani, 2011; Rocha et
al., 1996; Woolverton et al., 2001) and its abuse by humans appears to be confined to a small
fraction of drug users (Substance Abuse and Mental Health Services Administration, 2013) and a
narrow range of contexts (McCambridge et al., 2007; Winstock et al., 2012). Nonetheless, of the
more than 60 drugs from multiple drug classes that we have studied in this frequency-rate ICSS
procedure, ketamine is comparable only to ∆9-tetrahydrocannabinol and other cannabinoid-1
receptor agonists in its failure to facilitate ICSS despite evidence for reinforcing effects in assays
of drug self-administration (Kwilasz and Negus, 2013). It is possible that ketamine could
facilitate ICSS under other circumstances that have not yet been identified. For example, ∆9tetrahydrocannabinol effects on ICSS were reported to be strain- (Lepore et al., 1996) and dose(Katsidoni et al., 2013) dependent in rats. However, the present results with ketamine illustrate
the need for caution in extrapolating from ICSS studies to other preclinical assays of abuse
liability or to abuse potential in humans.
Experiment 3: Glutamatergic Antagonists and Involvement of Serotonin in the
Antidepressant-like Effects of Ketamine in the Differential-Reinforcement-of-low-Rate 72 s
Operant Procedure
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Rationale
Experiment 3 sought to evaluate the effects of other glutamatergic antagonists and to
determine the role of serotonergic mechanisms in the antidepressant-like effects of ketamine
using the DRL 72 s operant procedure. In the first study, the NMDA antagonists phencyclidine
and memantine and the AMPA antagonist NBQX were tested as comparators. Drug combination
studies then were conducted to determine the role of serotonin transporter and of serotonin 5-HT2
receptors in the antidepressant-like effects of ketamine in the DRL 72 s procedure. Most
clinically available antidepressant drugs (e.g. tricyclics, SSRIs, and SNRIs) share a common
pharmacological mechanism, which is inhibition of serotonin transporters. Ketamine has
virtually no affinity for serotonin transports (Ki = 161,700 nM) as compared to NMDA receptors
(Ki = 1,190 nM). The goal of this experiment was to determine if the antidepressant-like effects
of ketamine in the DRL 72 s procedure are mediated by inhibition of serotonin transporters. The
SSRI fluoxetine was used in combination with ketamine to evaluate the role of inhibiting
serotonin transporters in the antidepressant-like effects of ketamine.
Atypical antipsychotic drugs, which are serotonin 5-HT2 receptor antagonists, have been
shown to be efficacious as adjunctive treatment and display rapid effects for the remission of
depressive symptoms as compared to antidepressant drug treatment alone (Ostroff & Nelson,
1999; Tohen et al., 2010; Wright et al., 2013). The goal of this experiment was to determine if
the antidepressant-like effects ketamine in the DRL 72 s procedure are mediated by 5-HT2A
receptor antagonism. Ketamine has appreciable binding at serotonin 5-HT2 receptors (Ki =
15,000 nM) as compared to NMDA receptors (Ki = 1,190 nM); however, the functionality of
ketamine at 5-HT2 receptors is unknown (Kapur & Seeman, 2002). The serotonin 5-HT2 receptor
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antagonist ritanserin and serotonin 5-HT2 receptor agonist quipazine were used to determine the
role of serotonin 5-HT2 receptors in the antidepressant-like effects of ketamine.
Experiment 3 Methods
Subjects
Thirty-six adult male Sprague-Dawley rats (Harlan Laboratories Inc, Frederick, MD)
weighing between 300 and 350 grams at the start of the experiment were used in this study (see
methods for experiment 1 for further details). All experimental procedures were approved by the
Institutional Animal Care and Use Committee at Virginia Commonwealth University (IACUC
Protocol AM10215) and conducted in accordance with National Institutes of Health Guide for
the Care and Use of Laboratory Animals (Institute of Laboratory Animals Resources, 2011).
Apparatus
Four operant conditioning chambers (29.2 x 30.5 x 24.1 cm) enclosed in sound
attenuating cubicles were used (Model ENV-008-VP, Med-Associates). These operant
conditioning chambers were the same operant chambers used in experiment 1 (see methods for
experiment 1 for further details).
Drugs
The noncompetitive NMDA receptor antagonists (±) ketamine HCl (Sigma Aldrich), (+)
MK-801 maleate (Sigma Aldrich), phencyclidine HCl (Sigma Aldrich), and memantine (Sigma
Aldrich), and the 5-HT2 agonist quipazine dimaleate (Research Biochemical International,
Natick, MS) were dissolved in 0.9% physiological saline. The 5-HT2 antagonist ritanserin
(Sigma Aldrich) was dissolved in deionized water with two drops of 85% DL lactic acid. Sodium
hydroxide (Sigma Aldrich) was used as a buffer to insure a pH level of approximately 7.0. The
AMPA antagonist NBQX was suspended in deionized water with two drops of tween 80 (Sigma
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Aldrich). All drugs were administered intraperitoneally at a volume of 1.0 ml/kg and doses
represent the salt forms of the drugs. Testing of each drug was completed before initiating testing
with another drug. Doses and pretreatment times were based on preliminary studies and previous
studies in the literature (Carlezon & Wise, 1993; Hillhouse and Porter, 2014; Marek, Li, &
Seiden, 1989a; Marek et al., 1989b; Sanger, 1992). Drugs, doses, and pretreatment times were as
follows: ketamine (1.0-10.0 mg/kg; 5 min), MK-801 (0.032-0.18 mg/kg; 15 min), phencyclidine
(0.32-10.0 mg/kg; 30 min), memantine (1.0-10.0 mg/kg; 30 min), quipazine (0.56-5.6 mg/kg; 30
min), ritanserin (0.32-10.0 mg/kg; 60 min), and NBQX (1.0-10.0 mg/kg; 30 min). Pretreatment
time was the same for dose-effect and combination studies. Dose order was counterbalanced
using a Latin-square design.
Training and Testing Procedures
All training and testing procedures were identical to experiment 1 (see experiment for
further details). Test sessions occurred twice weekly (typically Tuesday and Friday) with a
minimum of one training sessions prior to each test session. Testing of any one drug was
completed before initiating testing with another drug, and a saline baseline was determined for
each drug tested. Testing continued until each drug had been tested in groups of 6-8 rats.
Statistical Analysis
The dependent variables included 1) total number of earned reinforcers during each test
session, 2) total number of responses during each test session, and 3) inter-response times (IRT)
for all responses during each test session. All data were expressed as means (+/- standard error of
the mean [S.E.M.]). Time bin data was not analyzed for this study. Response and reinforcer data
were analyzed using a one-way repeated measures analysis of variance (ANOVA). The IRT
distributions were obtained by recording responses in 25 6-s bins, with the first 6 s bin
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representing “burst responding”. To determine if there was a shift in the IRT distribution, a peak
location analysis was performed. Specifically, the median of the IRT distribution for each
individual rat was determined after eliminating burst responses from the total number of
responses. Medians (peak location) were analyzed using one-way repeated measures ANOVA
for dose (for more information on IRT analysis see Richards et al., 1993). For the IRT graphs,
the relative frequency for each 6 s bin was found for each rat (total number of responses divided
by number of responses for each time bin) and then averages were calculated for each bin.
Planned multiple comparisons using Tukey post hoc tests were conducted after all significant
ANOVAs, as appropriate. For combination studies, paired t-tests were conducted between
control conditions and the reference dose to determine if the drug effect was maintained. Oneway repeated measures ANOVA were conducted on reference dose and combinations (control
condition was not included in the ANOVA). The criterion for significance was p < 0.05. Data
were analyzed using GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego,
CA, USA).
Experiment 3 Results
DRL training and baseline performance. Twenty-eight rats met the DRL training
criterion in a mean of 22.32 (± 1.12 SEM) training sessions. Eight rats failed to meet training
criterion and, therefore, were not included in drug experiments.
Ketamine. The low-affinity NMDA receptor antagonist ketamine produced a significant
dose-dependent increase in the number of reinforcers earned (F[3,45] = 21.28, p < 0.001; Figure
15a), decrease in the number of responses emitted (F[3,45] = 21.09, p < 0.001; Figure 15b), and
rightward shift of the peak location on the IRT distribution (F[3,45] = 22.38, p < 0.001; Figure
15c). Specifically, compared to saline, treatment with 5.6 mg/kg ketamine increased reinforcers
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(p < 0.05), decreased responses (p < 0.01), and produced a rightward shift in the peak location of
the IRT distributions (p < 0.01). Additionally, 10.0 mg/kg ketamine increased reinforcers,
decreased responses, and produced a rightward shift in the peak location of the IRT distributions
as compared to saline and all other doses (p < 0.01).
Phencyclidine. The high-affinity NMDA receptor antagonist phencyclidine produced a
significant increase in the number of reinforcers earned (F[3,24] = 7.77, p < 0.001; Figure 15d)
and significantly decreased the number of responses emitted (F[3,24] = 4.64, p = 0.011; Figure
15e), but did not produce a significant effect on the peak location of the IRT distributions
(F[3,24] = 2.44, p = 0.089; Figure 15f). The 10.0 mg/kg dose of phencyclidine significantly
increased reinforcers (p < 0.001) and decreased responses (p < 0.05) as compared to saline.
Memantine. The low-affinity NMDA receptor antagonist memantine produced a
significant increase in the number of reinforcers earned (F[3,18] = 16.00, p < 0.001; Figure 15h),
a significant decrease in the number of responses emitted (F[3,18] = 11.99, p < 0.001; Figure
15i), and produced a significant shift in the peak location of the IRT distributions (F[3,18] =
13.51, p < 0.001; Figure 15j). Specifically, treatment with the 10.0 mg/kg dose of memantine
increased reinforcers (p < 0.001), decrease responses (p < 0.05), and produced a rightward shift
in the peak location of the IRT disruptions (p < 0.01) as compared to saline and all other doses.
NBQX. The AMPA receptor antagonist NBQX significantly increased the number of
reinforcers earned (F[3,27] = 3.60, p = 0.026) with the 3.2 mg/kg dose of NBQX increasing
reinforcers as compared to saline (p < 0.05; Figure 16a). NBQX failed to significantly alter the
number of responses emitted (F[3,27] = 2.66, p = 0.068; Figure 16b) or shift the peak location of
the IRT distributions (F[3,27] = 3.60, p = 0.026; Figure 16c).
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Figure 15. Effects of ketamine, phencyclidine, and memantine on DRL 72 s performance. Left
panels (a, d, h) show drug effects on number of reinforcers earned. Center panels (b, e, i) show
drug effects on number of responses emitted. Right panels (c, f, j) show drug effects on
interresponse time (IRT) distributions. Filled points represent significant shifts in peak location
after drug treatment as determined by peak location analysis followed by a Tukey post hoc test, p
< 0.05. Other details as in Figures 4. Reinforcers and responses are expressed as means ± S.E.M
for 7-16 rats (ketamine, n = 16; phencyclidine, n = 10; memantine, n = 7). IRT data are
expressed as means. *p < 0.05, **p < 0.01, ***p < 0.001 versus saline; ++p < 0.01, +++p <
0.001 versus all doses.
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Figure 16. Effects of NBQX on DRL 72 s performance. Left panel (a) show drug effects on
number of reinforcers earned. Center panel (b) show drug effects on number of responses
emitted. Right panel (c) show drug effects on interresponse time (IRT) distributions. Other
details as in Figures 4. Reinforcers and responses are expressed as means ± S.E.M for 10 rats.
IRT data are expressed as means. *p < 0.05 versus saline.
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Fluoxetine and ketamine combination. When administered alone, fluoxetine produced
a significant increase in the number of reinforcers earned (F[3,18] = 9.16, p < 0.001; Figure 17a),
a significant decrease in the number of responses made (F[3,18] = 7.09, p = 0.002; Figure 17b),
and produced a significant rightward shift in the peak location of the IRT distributions (F[3,18] =
4.53, p < 0.016; Figure 17c). Consistent with experiment 1, the 10.0 mg/kg dose of fluoxetine
increased reinforcers (p < 0.001), decreased responses (p < 0.01), and produced a rightward shift
in the peak location of the IRT distributions (p < 0.05). To determine if the antidepressant-like
effects produced by ketamine in the DRL 72 s procedure are mediated by blocking serotonin
reuptake, an ineffective dose of ketamine (3.2 mg/kg) was administered in combination with
fluoxetine (2.5-10.0 mg/kg). Treatment with saline + 3.2 mg/kg ketamine combination was not
significantly different from the control treatment on reinforcers (t[6] = 0.83, p = 0.436),
responses (t[6] = 0.12, p = 0.907), or the peak location of the IRT distributions (t[6] = 0.79, p =
0.457) (data not shown). The combination of fluoxetine + 3.2 mg/kg ketamine produced a
significant increase in the number of reinforcers earned (F[3,18] = 3.86, p = 0.027; Figure 17d),
but did not produce a significant effect on responses (F[3,18] = 2.93, p = 0.062; Figure 17e) or
IRT distributions (F[3,18] = 1.52, p = 0.242; Figure 17f). Specifically, only the combination of
10.0 mg/kg fluoxetine + 3.2 mg/kg ketamine significantly increased reinforcers as compared to
the saline + 3.2 mg/kg ketamine combination (p < 0.05).
Ritanserin and quipazine combination. When administered alone, ritanserin (1.0-10.0
mg/kg) did not produce a significant effect on reinforcers (F[4,28] = 0.34, p = 0.846; Figure
18a), responses (F[4,28] = 0.79, p = 0.54; Figure 18b), or IRT distributions (F[4,28] = 0.48, p =
0.751; Figure 18c). Ritanserin testing did not continue beyond the 10.0 mg/kg dose because this
dose far exceeded doses of ritanserin (0.16-0.64 mg/kg) previously tested in DRL 72 (Marek et
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al., 1989b) and drug solubility became an issue at doses exceeding 10.0 mg/kg. When
administered alone, quipazine did not significantly alter the number of reinforcers earned
(F[4,28] = 2.33, p = 0.08; Figure 18d), but quipazine did produce a significant decrease in the
number of responses emitted (F[4,28] = 15.34, p < 0.001; Figure 18e) and produced a significant
shift in the IRT distributions (F[4,24] = 2.76, p = 0.048; Figure 18f). Treatment with 5.6 and
10.0 mg/kg quipazine significantly decreased responses as compared to saline (p < 0.05). A
Tukey post hoc test failed to reveal a significant difference between doses for the significant
effect on IRT distributions; however, as shown in figure 18f, the 5.6 and 10.0 mg/kg dose of
quipazine appear to be producing a rightward/downward shift in the IRT distribution.
Combination tests were conducted to determine that the doses of ritanserin tested were
behaviorally active doses, and to further determine that both ritanserin and quipazine were
exerting their behavioral effects at 5-HT2 receptors. In order to determine if ritanserin could
antagonize the decrease in responses produced by 10.0 mg/kg quipazine, ritanserin (0.1-1.0
mg/kg) was co-administered with the 10.0 mg/kg dose of quipazine. Treatment with ritanserin
vehicle + 10.0 mg/kg quipazine combination did not significantly alter the number of reinforcers
earned (t[6] = 1.72, p = 0.137), but did produce a significant decrease in the number of responses
emitted compared to the control condition (t[6] = 7.23, p < 0.001). The ritanserin vehicle + 10.0
mg/kg quipazine combination failed to produce a significant shift in the peak location of the IRT
distributions (t[6] = 2.26, p = 0.065) (data not shown). The combination of ritanserin + 10.0
mg/kg quipazine did not produce a significant effect in the number of reinforcers earned (F[3,18]
= 1.60, p = 0.22; Figure 18h), but did produce a significant effect in the number of responses
emitted (F[3,18] = 19.37, p < 0.001; Figure 18i) and produced a significant shift in the IRT
distributions (F[3,18] = 4.68, p = 0.014; Figure 18j). Specifically, all three doses of ritanserin
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Figure 17. Effects of fluoxetine and the fluoxetine + 3.2 mg/kg ketamine combination on DRL
72 s performance. Left panels (a, d) show drug effects on number of reinforcers earned. Center
panel (b, e) show drug effects on number of responses emitted. Right panels (c, f) show drug
effects on interresponse time (IRT) distributions. Filled points represent significant shifts in peak
location after drug treatment as determined by peak location analysis followed by a Tukey post
hoc test, p < 0.05. Other details as in Figures 4. Reinforcers and responses are expressed as
means ± S.E.M for seven rats. IRT data are expressed as means. *p < 0.05, **p < 0.01, ***p <
0.001 versus saline (or saline + 3.2 mg/kg ketamine [d]); +p < 0.05 versus all doses.
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Figure 18. Effects of ritanserin, quipazine and the ritanserin + 10.0 mg/kg quipazine combination
on DRL 72 s performance. Left panels (a, d, h) show drug effects on number of reinforcers
earned. Center panel (b, e, i) show drug effects on number of responses emitted. Right panels (c,
f, j) show drug effects on interresponse time (IRT) distributions. Filled points represent
significant shifts in peak location after drug treatment as determined by peak location analysis
followed by a Tukey post hoc test, p < 0.05. Other details as in Figures 4. Reinforcers and
responses are expressed as means ± S.E.M for seven to eight rats (ritanserin, n = 8; quipazine, n
= 8; ritanserin + 10.0 mg/kg quipazine, n = 7). IRT data are expressed as means. *p < 0.05, ***p
< 0.001 versus vehicle (or vehicle + 10.0 mg/kg quipazine [i]); +p < 0.05 versus all doses.
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(0.1-1.0 mg/kg) significantly increased responses (p < 0.001) and produced a leftward/upward
shift in the peak location of the IRT distributions (p < 0.05) as compared to ritanserin vehicle +
10.0 mg/kg quipazine.
Ritanserin and ketamine combination. To determine if the antidepressant-like effects
produced by ketamine in the DRL 72 s procedure were mediated by antagonism of 5-HT2
receptors, an ineffective dose of ketamine (3.2 mg/kg) was administered in combination with the
5-HT2 antagonist ritanserin (0.32-3.2 mg/kg). Treatment with ritanserin vehicle + 3.2 mg/kg
ketamine combination was not significantly different from the control conditions on reinforcers
(t[7] = 0.43, p = 0.68), responses (t[7] = 0.06, p = 0.96), or the peak location of the IRT
distributions (t[7] = 0.68, p = 0.52) (data not shown). The combination of ritanserin + 3.2 mg/kg
ketamine did not produce a significant effect (although there was a trend toward significance) in
the number of reinforcer earned (F[3,21] = 2.80, p = 0.065; Figure 19a), but did produce a
significant decrease on the number of responses emitted (F[3,21] = 3.63, p = 0.029; Figure 19b).
The combination of ritanserin + 3.2 mg/kg ketamine did not produce a significant shift in the
peak location of the IRT distributions (F[3,21] = 1.78, p = 0.181; Figure 19c). Specifically, the
combination of 1.0 mg/kg ritanserin + 3.2 mg/kg ketamine significantly decreased responses as
compared to the ritanserin vehicle + 3.2 mg/kg ketamine combination (p < 0.05).
Quipazine and ketamine combination. To determine if the antidepressant-like effects
produced by ketamine in the DRL 72 s procedure were mediated by antagonism of 5-HT2
receptors, an effective dose of ketamine (10.0 mg/kg) was administered in combination with the
5-HT2 agonist quipazine (0.56-5.6 mg/kg). This combination was used to determine if quipazine
could block the antidepressant-like effects of ketamine. As compared to control conditions,
treatment with saline + 10.0 mg/kg ketamine combination significantly increased reinforcers
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(t[7] = 3.87, p = 0.006), decreased responses (t[7] = 2.99, p = 0.02), and produced a rightward
shift in the peak location of the IRT distributions (t[7] = 3.07, p = 0.018) (data not shown). The
combination of quipazine + 3.2 mg/kg ketamine did not produce a significant effect in the
reinforcer earned (F[3,21] = 0.58, p = 0.636; Figure 19d), but did produced a significant decrease
on the number of responses emitted (F[3,21] = 10.47, p < 0.001; Figure 19e). The combination
of quipazine + 3.2 mg/kg ketamine failed to significantly shift the peak location of the IRT
distributions (F[3,21] = 1.88, p = 0.164; Figure 19f). Specifically, the combination of 5.6 mg/kg
quipazine + 10.0 mg/kg ketamine significantly decreased responses as compared to all quipazine
+ 10.0 mg/kg ketamine combination (p < 0.01).
Ritanserin and MK-801 combination. The 5-HT2A receptor antagonist M100907 has
been shown to attenuate the psychostimulant-like effects (i.e. increase in responses, decrease in
reinforcers and leftward shift in the IRT distributions) produced by MK-801 in the DRL 72 s
procedure (Ardayfio et al 2008). In the present study, the combination of the 5-HT2 receptor
antagonist ritanserin and 0.18 mg/kg MK-801 was used to determine if ritanserin could block the
behavioral effects of NMDA antagonists. Additionally, this combination was used to determine
if 5-HT2 receptors were mediating the dissociable effects produced by ketamine and MK-801 in
the DRL 72 s procedure. Treatment with the ritanserin vehicle + 0.18 mg/kg MK-801
combination significantly increased responses (t[6] = 5.07, p = 0.002), but did not significantly
alter reinforcers (t[6] = 1.68, p = 0.144) as compared to control conditions. Additionally, the
ritanserin vehicle + 0.18 mg/kg MK-801 combination produced a leftward shift in the peak
location of the IRT distributions (t[6] = 6.13, p < 0.001) as compared to control conditions (data
not shown). Treatment with 1.0 mg/kg ritanserin + 0.18 mg/kg MK-801 combination
significantly decreased responses (t[6] = 4.19, p = 0.006; Figure 20b), but did not significantly
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Figure 19. Effects of the ritanserin + 3.2 mg/kg ketamine and quipazine + 10.0 mg/kg ketamine
combination on DRL 72 s performance. Left panels (a, d) show drug effects on number of
reinforcers earned. Center panel (b, e) show drug effects on number of responses emitted. Right
panels (c, f) show drug effects on interresponse time (IRT) distributions. Other details as in
Figures 4. Reinforcers and responses are expressed as means ± S.E.M for eight rats. IRT data are
expressed as means. *p < 0.05, **p < 0.01 versus vehicle + 3.2 mg/kg ketamine [b] (or vehicle +
10.0 mg/kg ketamine [e]); +++p < 0.001 versus all doses.
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Figure 20. Effects of the ritanserin + 0.18 mg/kg MK-801 combination on DRL 72 s
performance. Left panels (a) show drug effects on number of reinforcers earned. Center panel (b)
show drug effects on number of responses emitted. Right panels (c) show drug effects on
interresponse time (IRT) distributions. Other details as in Figures 4. Reinforcers and responses
are expressed as means ± S.E.M for seven rats. IRT data are expressed as means. **p < 0.01
versus vehicle + 0.18 mg/kg MK-801.
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alter reinforcers (t[6] = 0.82, p = 0.441; Figure 20a). The 1.0 mg/kg ritanserin + 0.18 mg/kg MK801 combination produced a significant rightward shift in the peak location of the IRT
distributions (t[6] = 5.29, p = 0.002; Figure 20c).
Experiment 3 Discussion
Experiment 3 used a DRL 72 s procedure to compare the antidepressant-like effects of
the noncompetitive NMDA receptor antagonists ketamine, phencyclidine, and memantine, as
well as the AMPA receptor antagonist NBQX. Additionally, this study evaluated the
involvement of serotoninergic mechanisms in the antidepressant-like effects of ketamine in the
DRL 72 s procedure. There were three main findings. First, the three noncompetitive NMDA
receptor antagonists, but not the AMPA receptor antagonist, produced antidepressant-like effects
in the DRL 72 s procedure. Specifically, ketamine and memantine increased reinforcers,
decreased responses, and produced a rightward shift in IRT distributions; whereas, phencyclidine
increased reinforcers and decreased responses, but failed to shift the IRT distributions. The
AMPA antagonist NBQX did increase reinforcers, but failed to alter responses or shift the IRT
distributions. Second, the antidepressant-like effects of ketamine in the DRL 72 s procedure do
not appear to be mediated by inhibiting the reuptake of serotonin via serotonin transporters or
antagonism of 5-HT2 receptors. Specifically, the SSRI fluoxetine and the 5-HT2 receptor
antagonist ritanserin failed to potentiate an ineffective dose of ketamine and the 5-HT2 agonist
quipazine failed to attenuate the antidepressant-like effects produced by 10.0 mg/kg ketamine in
the DRL 72 s procedure. Third, the psychostimulant-like effects of MK-801 in the DLR 72 s
procedure are, in part, mediated by 5-HT2 receptors. Specifically, the 5-HT2 receptor antagonist
ritanserin attenuated the increase in responses and leftward shift in the IRT distribution for MK801. Taken together, these findings suggest NMDA receptor antagonism, not AMPA receptor
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antagonism, produces antidepressant-like effects in the DRL 72 s procedure. Additionally, the
dissociable effects of ketamine and MK-801 in the DRL 72 s procedure may be mediated by 5HT2 receptors.
The present study is the first to report on the effects of phencyclidine in the DRL 72 s
procedure. While the 10.0 mg/kg dose of phencyclidine increased reinforcers and decreased
responses, it did not shift the IRT distribution. These phencyclidine effects are similar to effects
of selective serotonin reuptake inhibitors (SSRIs), which increase reinforcement rate and
decrease response rate, but often do not significantly shift the IRT distributions (O’Donnell et al.,
2005; Sokolowski & Seiden, 1999). Other antidepressants, such as tricyclic antidepressants and
MAO inhibitors, consistently increase reinforcement rate, decrease response rate, and produce a
rightward shift in the IRT distribution (O’Donnell et al., 2005). In contrast to the antidepressantlike effects of phencyclidine in the preset study, a higher phencyclidine dose (15.0 mg/kg) did
not alter time spent immobile in the forced swim test in rats, suggesting that phencyclidine did
not produce an antidepressant-like effect in that procedure (Turgeon, Lin, & Subramanian,
2007).
The DRL 72 s behavioral profile produced by phencyclidine also differs from the effects
of the other noncompetitive NMDA antagonists MK-801 and ketamine. Ketamine produces an
antidepressant-like effect in rats maintained under a DRL 72 s schedule by increasing
reinforcers, decreasing responses, and producing a rightward shift in the IRT distribution (in
experiments 1 and 3), which is consistent with other preclinical studies evaluating the
antidepressant-like effects of ketamine (Autry et al., 2011; Engin et al., 2009; Gigliucci et al.,
2013; Li et al., 2011; Maeng et al., 2007; Tizabi et al., 2012). Conversely, MK-801 produces a
stimulant-like behavioral profile in DRL 72 s, which is characterized by a decrease in
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reinforcers, increase in responses, and a leftward shift in the IRT distribution. Thus, in the DRL
72 s procedure, phencyclidine effects were more similar to those of ketamine than to MK-801,
although phencyclidine failed to produce the antidepressant-like rightward shift in IRT
distributions.
The present study is the first to report on the effects of memantine in the DRL 72 s
procedure. The results of memantine in the present study on DRL 72 s responding are similar to
the effects produced by ketamine and other antidepressants (e.g. tricyclic antidepressants and
MAO inhibitors) that increase reinforcement rate, decrease response rate, and produce a
rightward shift in the IRT distributions. Furthermore, the antidepressant-like effects of
memantine in the present study are consistent with the antidepressant-like effects produced by
memantine in other preclinical procedures, such as forced swim test, chronic mild stress, and
adrenocorticotropic hormone-induced behavioral deficits (Moryl, Danysz, & Quack, 1993; Quan,
Zhang, Wang, Zhang, & Yang, 2011; Reus et al., 2010; Reus et al., 2012; Tokita, Fujita, Yamaji,
& Hashimoto, 2012). For example, acute and chronic treatment with memantine in rats reduced
time spent immobile in the forced swim procedure at doses that did not increase locomotor
activity (Reus et al., 2012). However, the clinical efficacy of memantine remains unclear.
Several clinical studies have reported that memantine was not superior to placebo (Lenze et al.,
2012; Zarate et al., 2006); however, one study found memantine to be as effective as the SSRI
escitalopram (Muhonen, Lonngvist, Juva, & Alho, 2008). Currently, memantine is being pursued
as a possible adjunctive treatment for MDD.
In the present study, the AMPA receptor antagonist NBQX increased reinforcers, but
failed to alter responses or IRT distributions. These results are different from the effects
produced by the noncompetitive NMDA receptor antagonists ketamine, MK-801, phencyclidine,
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and memantine, but are consistent with the behavioral effects of NBQX in other preclinical
procedures used to assess the antidepressant-like effects of drugs such as the forced swim test,
learned helplessness procedure and tail suspension test (Autry et al., 2011; Koike et al., 2011;
Maeng et al., 2008). For example, a high dose of NBQX (10.0 mg/kg) did not alter time spent
immobile in the forced swim (Autry et al., 2011; Maeng et al., 2008) or tail suspension test
(Koike et al., 2011) tests in mice, and NBQX did not reduce the number of escape failures in the
learned helplessness inescapable shock procedure in rats (Koike et al., 2011); however, ketamine
did produce an antidepressant-like effect in these studies (Autry et al., 2011; Koike et al., 2011;
Maeng et al., 2008). Taken together with the present findings, these results further support the
hypothesis that NMDA receptor antagonism, not AMPA receptor antagonism, is responsible for
the antidepressant-like effects of ketamine and other NMDA receptor antagonists.
In experiment 3, fluoxetine produced effects consistent with experiment 1 in which
fluoxetine produced an antidepressant-like effect by increasing the number of reinforcers,
decreasing the number of responses, and producing a rightward shift in the IRT distribution. The
combination of fluoxetine + 3.2 mg/kg ketamine was used to determine the role of the inhibiting
the serotonin transporter in the antidepressant-like effects of ketamine on DRL 72 s responding.
This combination of 10.0 fluoxetine + 3.2 mg/kg ketamine produced an increase in the number
of reinforcers, but did not alter responses or shift the IRT distribution. The lower doses of
fluoxetine (2.5-5.0) did not potentiate the effects of the sub-effective ketamine on any of the
dependent measures. These findings are in contrast to a previous report that the combination of
the SSRI fluvoxamine and ketamine produced an additive effect by decreasing immobility time
on the forced swim behavior in mice (Chaturvedi, Bapna, & Chandra, 2001). While the
differences may be due to different drugs and procedures being used, another major difference
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between these studies is that Chaturvedi et al. (2001) administered low, but effective doses of
both fluvoxamine and ketamine when administered alone. The present study used an ineffective
dose of ketamine and thus, it is possible that combining fluoxetine and 10.0 mg/kg ketamine may
have yielded different results. Furthermore, ketamine is approximately 150-fold more selective
for NMDA receptors as compared to serotonin transports (see table 5), and Martin et al. (1982)
found that a high dose of ketamine (>80.0 mg/kg) is required to inhibit the serotonin transporter
in rats. Thus, the results from the present study would suggest that inhibition of serotonin
transporters does not appear to play a role in the antidepressant-like effects of ketamine in the
DRL 72 s procedure.
In the experiment 3, the 5-HT2 receptor antagonist ritanserin failed to significantly alter
reinforcers, responses, and the peak location of the IRT distributions; whereas, the 5-HT2 agonist
quipazine decreased the number of responses, but did not significantly increase the number of
reinforcers or produce a rightward shift in the IRT distributions. These results contrast previous
reports that ritanserin increased reinforcers and decreased responses in rats in the DRL 72 s
procedure (Marek et al., 1989b). Although ritanserin did not produce a behavioral effect when
administered alone in the present study, low doses of ritanserin (0.1-1.0 mg/kg) blocked the
decrease in responses produced by 10.0 mg/kg quipazine. The combination of ritanserin or
quipazine with ketamine was used to determine if the antidepressant-like effects of ketamine in
the DRL 72 s procedure was a result of antagonism of the 5-HT2 receptors. Specifically, 1.0
mg/kg ritanserin + 3.2 mg/kg ketamine decreased the number of responses emitted, but did not
significantly increase reinforcers (although there was a trend toward significance, p = 0.06) or
shift the IRT distributions. Additionally, quipazine failed to block the antidepressant-like effects
of ketamine in the DRL 72 s procedure, and was found to further decrease responding at a dose
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that decreased responding when administered alone. The results from the present study are
similar to the effects produced by the combination of the 5-HT2 antagonist ketanserin and
ketamine in the forced swim test in which this combination produced a modest, although not
significantly different from when each drug was administered alone, additive decrease in time
spent immobile on the forced swim behavior in mice (Chaturvedi et al., 2001). Several studies
have shown that ketamine binds to serotonin 5-HT2 receptors (Martin, Bouchal, & Smith, 1982;
Kapur & Seeman, 2002; Sakai et al., 2013); however, the functionality of ketamine at 5-HT2
receptors is unknown. The results from the present study suggest that 5-HT2 receptors do not
play a major role in the antidepressant-like effects of ketamine.
The results from the ritanserin + 0.18 mg/kg MK-801 combination data are consistent
with a previous report that found the 5-HT2A receptor antagonist M100907 attenuated the
psychostimulant-like effects of MK-801 (Ardayfio et al 2008). In the present study, 1.0 mg/kg
ritanserin attenuated the psychostimulant-like effects of MK-801 by decreasing responses to
control levels and shifted the IRT distributions to the right. Thus, the dissociable effects of
ketamine and MK-801 in the DRL 72 s procedure may be mediated by 5-HT2 receptors. The
results from the present study suggest that MK-801 activates the 5-HT2 receptor, although it is
unclear if MK-801 directly or indirectly activates the 5-HT2 receptors; whereas, the effects of
ketamine on 5-HT2 receptors have yet to be fully elucidated.
General Discussion
The results from the present series of experiments add to the body of literature examining
the behavioral effects of NMDA receptor antagonists, and found dissociable differences in terms
of antidepressant-like and abuse-related effects of these drugs. The most notable difference
found in the present series of experiments was between ketamine and MK-801. Specifically,
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ketamine produced an antidepressant-like profile in rats responding under a DRL 72 s schedule
of reinforcement, whereas MK-801 did not (experiments 1 and 3). Conversely, ketamine failed to
produce an abuse-related facilitation of ICSS, whereas MK-801 did (experiment 2). Experiment
3 provided further evidence for dissociable behavioral effects in the DRL 72 s procedure in that
the 5-HT2 receptor antagonist ritanserin attenuated the psychostimulant-like effect produced by
MK-801; whereas, ritanserin produced minimal changes in the behavioral effects of ketamine.
Future studies need to evaluate other receptor mechanisms that may mediate these behavioral
differences. For example, ketamine has moderate binding affinity for the sigma receptors as
compared to NMDA receptors (see table 5) (Robson et al., 2012; Smith et al., 1987); whereas,
MK-801 has no significant binding at sigma receptors (Okuyama et al., 1995). Additionally, the
effects of ketamine at the sigma receptor appear to play a role in the discriminative stimulus
properties of ketamine in rats and neurite outgrowth in vitro (Narita et al., 2001; Robson et al.,
2012).
Second, future studies need to compare ketamine and MK-801 in several other preclinical
procedures used to assess the antidepressant-like effects of drugs. For example, MK-801 has
been shown to produce antidepressant-like effects in the forced swim test (Autry et al., 2011;
Engin et al., 2009; Maeng et al., 2008); however, the present studies found that MK-801 did not
produce an antidepressant-like effect in the DRL 72 s procedure. MK-801 has only served as a
comparator for the antidepressant-like effects of ketamine in the forced swim test and DRL 72 s
procedure. It will be important to compare ketamine and MK-801, as well as other NMDA
antagonists, in the chronic mild stress, chronic unpredictable stress, and learned helplessness
assays, which require repeated dosing of the clinically available antidepressant drug before
deficits in anhedonia-like behaviors are reversed. Interestingly, a single administration of
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ketamine can produce rapid and sustained antidepressant-like effects in these preclinical assays
(i.e. chronic mild stress, chronic unpredictable stress, and learned helplessness) (Li et al., 2011;
Maeng et al., 2007; Koike et al., 2011). The effects of MK-801 have not been assessed in any of
these preclinical procedures (e.g. chronic mild stress, chronic unpredictable stress, and learned
helplessness). To truly understand the antidepressant potential of these drugs, it is important to
use a variety of preclinical procedures and to assess the data as a whole, rather than rely on only
one or two procedures.
The results from the present series of experiments provided evidence that noncompetitive
NMDA receptor antagonists, but not AMPA receptor antagonists, produce antidepressant-like
effects in the DRL 72 s procedure. Specially, the two low-affinity NMDA receptor antagonists
ketamine and memantine produced full antidepressant-like effects; whereas the higher-affinity
NMDA receptor antagonist phencyclidine produced a partial antidepressant-like effect as it did
not shift the IRT distributions. The results from the combinations studies suggest that the acute
antidepressant-like effects of ketamine are not produced by inhibiting serotonin transporters or
antagonism of 5-HT2 receptors, which is consistent with a previous report that found serotonin
was not required for the acute antidepressant-like effects of ketamine on forced swim behavior in
rats (Gigliucci et al., 2013), and further suggest that mechanisms responsible for the
antidepressant-like effects of ketamine may be novel and are not shared by fluoxetine.
To my knowledge, ketamine and memantine are the only two drugs from the present
studies that have been evaluated in clinical research settings for antidepressant efficacy and
ketamine has produced superior clinical efficacy over memantine. For example, several clinical
studies have shown that ketamine produces rapid and sustained antidepressant effects following
subanesthetic intravenous infusion in patients suffering from MDD (ann het Rot et al., 2010;
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Berman et al., 2000; Murrough et al., 2013; Murrough et al., 2013; Zarate et al., 2006).
Memantine, which is a selective low-affinity NMDA receptor antagonist, did not produce rapid
or sustained antidepressant effects in clinical research. In fact, two clinical studies found that
memantine was not superior to placebo (Lenze et al., 2012; Zarate et al., 2006). A single clinical
study found that memantine produced antidepressant effects in patients suffering from MDD, but
it was not superior to the SSRI escitalopram (Muhonen, Lonngvist, Juva, & Alho, 2008).
Furthermore, memantine failed to produce rapid or sustained antidepressant effects in these
studies. Although ketamine and memantine possess similar binding affinity for the NMDA
receptors and produced similar effects in the DRL 72 s procedure, ketamine and memantine
produce dissociable effects in clinical research.
While the present results demonstrated that phencyclidine produced partial
antidepressant-like effects in the DRL 72 s procedure (experiment 3), there is little preclinical
research assessing the antidepressant-like effects of phencyclidine, and it is unlikely that
phencyclidine will be tested in human studies because of abuse liability concerns (Olthuis,
Darredeau, & Barrett, 2013; Substance Abuse and Mental Health Services Administration,
2013). Several other NMDA receptor antagonists have been evaluated in clinical research
settings for their antidepressant efficacy, but the results have been not been promising with most
drugs failing to produce rapid and/or sustained antidepressant effects (Ibrahim et al., 2012;
Preskorn et al., 2008; Zarate et al., 2013). For example, a study evaluating the antidepressant
efficacy of the selective NMDA NR2B antagonist MK-0657 was terminated after only 5 patients
completed the both phases of the study because of recruitment challenges and because the
manufacturer discontinue the development of the compound (Ibrahim et al., 2012). In addition,
the low-trapping NMDA channel blocker AZD6765 produced rapid (at 80 min) antidepressant
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effects following a single infusion, but these antidepressant effects dissipated by 230 mins
(Zarate et al., 2013). There is, however, one glutamatergic compound that has shown
antidepressant efficacy similar to that of ketamine in patients suffering from MDD. The glycinesite partial agonist, GLYX-13, produced rapid and sustained antidepressant effects following a
single infusion, and most importantly, did not produce psychotomimetic effects. The
antidepressant effects of GLYX-13 are apparent at the end of day one and persist until day seven
(Moskal et al., 2014). Currently, a 12-week repeated-dosing Phase IIb clinical trial is underway.
Taken together, these results indicate that the underlying mechanisms responsible for the clinical
antidepressant effects of ketamine may not be driven solely through NMDA receptor antagonism
and may be mediated by other receptor targets.
In conclusion, results from the present series of experiments found that the
noncompetitive NMDA receptor antagonists ketamine, MK-801, phencyclidine and memantine
produced dissociable behavioral effects in the DRL 72 s operant procedure. Our findings provide
further evidence that expression of these effects may be related to NMDA receptor affinity. For
example, the low-affinity antagonists ketamine (Ki = 1,190 nM) and memantine (Ki = 690 nM)
produced antidepressant-like effects in the DRL 72 s procedure with little evidence from ICSS
procedures for abuse potential (Hillhouse et al., 2014; Tzschentke & Schmidt, 1999); whereas,
the high-affinity antagonist MK-801 (Ki = 2.5 nM) failed to produce antidepressant-effects in the
DRL 72 s procedure, but did produce abuse-related ICSS facilitation of ICSS (Hillhouse et al.,
2014; Bresink et al., 1995). In comparison, phencyclidine has intermediate affinity at NMDA
receptors (Ki = 42 nM) (Bresink et al., 1995), and it produced a mixed-profile of behavioral
effects that included both partial antidepressant-like effects in the DRL 72 s procedure and
abuse-related facilitation of ICSS. Furthermore, the dissociable effects of ketamine and MK-801
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appear to be mediated by different pharmacological effects at 5-HT2 receptors. Specifically, the
psychostimulant-like effects of MK-801 in the DRL 72 s produce appear to be by 5-HT2 receptor
agonism; whereas, 5-HT2 receptors do not appear to play a role in the antidepressant-like effects
of ketamine in the DRL 72 s task. Taken together, these results indicate that the underlying
mechanisms responsible for the clinical antidepressant effects of ketamine may not be driven
solely through NMDA receptor antagonism and may be mediated by other receptor targets.
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